<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)</title>
				<funder>
					<orgName type="full">Entasis</orgName>
				</funder>
				<funder>
					<orgName type="full">Shionogi</orgName>
				</funder>
				<funder>
					<orgName type="full">MSD</orgName>
				</funder>
				<funder>
					<orgName type="full">Genentech</orgName>
				</funder>
				<funder>
					<orgName type="full">ESCMID</orgName>
				</funder>
				<funder>
					<orgName type="full">Pfizer</orgName>
				</funder>
				<funder>
					<orgName type="full">Gilead</orgName>
				</funder>
				<funder>
					<orgName type="full">Menarini</orgName>
				</funder>
				<funder>
					<orgName type="full">Merck</orgName>
				</funder>
				<funder>
					<orgName type="full">Wockhardt</orgName>
				</funder>
				<funder>
					<orgName type="full">Nabriva</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability  status="unknown">
					<licence/>
				</availability>
				<date type="published" when="2021-12-16">16 December 2021</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Mical</forename><surname>Paul</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Infectious Diseases Institute</orgName>
								<orgName type="institution">Rambam Health Care Campus</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">Technion e Israel Institute of Technology</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Elena</forename><surname>Carrara</surname></persName>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Diagnostic and Public Health</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Pilar</forename><surname>Retamar</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Departamento de Medicina</orgName>
								<orgName type="institution">Universidad de Sevilla</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Unidad Clínica de Enfermedades Infecciosas</orgName>
								<orgName type="institution" key="instit2">Microbiología y Medicina Preventiva</orgName>
								<orgName type="institution" key="instit3">Hospital Universitario Virgen Macarena/Instituto de Biomedicina de Sevilla (IBiS)</orgName>
								<address>
									<settlement>Seville</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Roni</forename><surname>Bitterman</surname></persName>
							<affiliation key="aff0">
								<orgName type="department">Infectious Diseases Institute</orgName>
								<orgName type="institution">Rambam Health Care Campus</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff1">
								<orgName type="department">Faculty of Medicine</orgName>
								<orgName type="institution">Technion e Israel Institute of Technology</orgName>
								<address>
									<settlement>Haifa</settlement>
									<country key="IL">Israel</country>
								</address>
							</affiliation>
							<affiliation key="aff5">
								<orgName type="department">Department of Medical Sciences</orgName>
								<orgName type="institution">Uppsala University</orgName>
								<address>
									<settlement>Uppsala</settlement>
									<country key="SE">Sweden</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Robert</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
							<affiliation key="aff6">
								<orgName type="department">Department of Medicine</orgName>
								<address>
									<settlement>Pharmacology</settlement>
								</address>
							</affiliation>
							<affiliation key="aff8">
								<orgName type="department">Medical Service, Research Service, and GRECC</orgName>
								<address>
									<addrLine>Louis Stokes Cleveland</addrLine>
								</address>
							</affiliation>
							<affiliation key="aff10">
								<orgName type="department">VAMC Center for Antimicrobial Resistance and Epidemiology</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jan</forename><surname>De Waele</surname></persName>
							<affiliation key="aff11">
								<orgName type="department">Department of Critical Care Medicine</orgName>
								<orgName type="institution">Ghent University Hospital</orgName>
								<address>
									<settlement>Ghent</settlement>
									<country key="BE">Belgium</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">George</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
							<affiliation key="aff12">
								<orgName type="department">First Department of Medicine</orgName>
								<orgName type="institution">National and Kapodistrian University of Athens</orgName>
								<address>
									<settlement>Athens</settlement>
									<country key="GR">Greece</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Murat</forename><surname>Akova</surname></persName>
							<affiliation key="aff13">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution">Hacettepe University School of Medicine</orgName>
								<address>
									<settlement>Ankara</settlement>
									<country key="TR">Turkey</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Harbarth</surname></persName>
							<affiliation key="aff14">
								<orgName type="department" key="dep1">Infection Control Programme</orgName>
								<orgName type="department" key="dep2">Hospitals and Faculty of Medicine</orgName>
								<orgName type="institution">University of Geneva</orgName>
								<address>
									<settlement>Geneva</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Celine</forename><surname>Pulcini</surname></persName>
							<affiliation key="aff15">
								<orgName type="institution" key="instit1">Universit e de Lorraine</orgName>
								<orgName type="institution" key="instit2">APEMAC</orgName>
								<address>
									<settlement>Nancy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
							<affiliation key="aff16">
								<orgName type="department">Infectious Diseases Department</orgName>
								<orgName type="institution" key="instit1">Universit e de Lorraine</orgName>
								<orgName type="institution" key="instit2">CHRU-Nancy</orgName>
								<address>
									<settlement>Nancy</settlement>
									<country key="FR">France</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><surname>Garnacho-Montero</surname></persName>
							<affiliation key="aff17">
								<orgName type="institution" key="instit1">Intensive Care Unit</orgName>
								<orgName type="institution" key="instit2">Virgen Macarena University Hospital</orgName>
								<address>
									<settlement>Seville</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Katja</forename><surname>Seme</surname></persName>
							<affiliation key="aff18">
								<orgName type="department" key="dep1">Institute of Microbiology and Immunology</orgName>
								<orgName type="department" key="dep2">Faculty of Medicine</orgName>
								<orgName type="institution">University of Ljubljana</orgName>
								<address>
									<country key="SI">Slovenia</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Mario</forename><surname>Tumbarello</surname></persName>
							<affiliation key="aff19">
								<orgName type="department">Department of Medical Biotechnologies</orgName>
								<orgName type="institution">University of Siena</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Paul</forename><forename type="middle">Christoffer</forename><surname>Lindemann</surname></persName>
							<affiliation key="aff20">
								<orgName type="department">Department of Microbiology</orgName>
								<orgName type="institution">Haukeland University Hospital</orgName>
								<address>
									<settlement>Bergen</settlement>
									<country key="NO">Norway</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Sumanth</forename><surname>Gandra</surname></persName>
							<affiliation key="aff21">
								<orgName type="department">Division of Infectious Diseases</orgName>
								<orgName type="institution">Washington University School of Medicine</orgName>
								<address>
									<settlement>St Louis St Louis</settlement>
									<region>MO</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Yunsong</forename><surname>Yu</surname></persName>
							<affiliation key="aff22">
								<orgName type="department">Department of Infectious Diseases</orgName>
								<orgName type="institution" key="instit1">Sir Run Run Shaw Hospital</orgName>
								<orgName type="institution" key="instit2">Zhejiang University School of Medicine</orgName>
								<address>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff23">
								<orgName type="department">Key Laboratory of Microbial Technology and Bioinformatics of Zhejiang Province</orgName>
								<address>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
							<affiliation key="aff24">
								<orgName type="department">School of Medicine</orgName>
								<orgName type="institution" key="instit1">Regional Medical Centre for National Institute of Respiratory Diseases</orgName>
								<orgName type="institution" key="instit2">Sir Run Run Shaw Hospital</orgName>
								<orgName type="institution" key="instit3">Zhejiang University</orgName>
								<address>
									<settlement>Hangzhou</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Matteo</forename><surname>Bassetti</surname></persName>
							<affiliation key="aff25">
								<orgName type="department">Department of Health Sciences</orgName>
								<orgName type="institution">University of Genoa</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff26">
								<orgName type="department">Clinica Malattie Infettive</orgName>
								<orgName type="institution">San Martino Policlinico Hospital</orgName>
								<address>
									<settlement>Genoa</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Johan</forename><forename type="middle">W</forename><surname>Mouton</surname></persName>
							<affiliation key="aff27">
								<orgName type="department">Department of Medical Microbiology and Infectious Diseases</orgName>
								<orgName type="institution">Erasmus MC</orgName>
								<address>
									<settlement>Rotterdam</settlement>
									<country key="NL">the Netherlands</country>
								</address>
							</affiliation>
						</author>
						<author role="corresp">
							<persName><forename type="first">Evelina</forename><surname>Tacconelli</surname></persName>
							<email>evelina.tacconelli@univr.it</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Diagnostic and Public Health</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
							<affiliation key="aff28">
								<orgName type="department" key="dep1">Division of Infectious Diseases</orgName>
								<orgName type="department" key="dep2">Department of Internal Medicine I</orgName>
								<orgName type="department" key="dep3">German Centre for Infection Research</orgName>
								<orgName type="institution">University of Tübingen</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff29">
								<orgName type="laboratory" key="lab1">German Centre for Infection Research (DZIF)</orgName>
								<orgName type="laboratory" key="lab2">Clinical Research Unit for Healthcare Associated Infections</orgName>
								<address>
									<settlement>Tübingen</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
							<affiliation key="aff30">
								<orgName type="department" key="dep1">Corresponding author. Evelina Tacconelli</orgName>
								<orgName type="department" key="dep2">Infectious Diseases Division</orgName>
								<orgName type="department" key="dep3">Diagnostics and Public Health Department</orgName>
								<orgName type="institution">University of Verona</orgName>
								<address>
									<addrLine>P.le L.A. Scuro 10</addrLine>
									<postCode>37134</postCode>
									<settlement>Verona</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">Jesús</forename><surname>Rodríguez-Ba Ño</surname></persName>
							<affiliation key="aff3">
								<orgName type="department">Departamento de Medicina</orgName>
								<orgName type="institution">Universidad de Sevilla</orgName>
								<address>
									<settlement>Sevilla</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
							<affiliation key="aff4">
								<orgName type="institution" key="instit1">Unidad Clínica de Enfermedades Infecciosas</orgName>
								<orgName type="institution" key="instit2">Microbiología y Medicina Preventiva</orgName>
								<orgName type="institution" key="instit3">Hospital Universitario Virgen Macarena/Instituto de Biomedicina de Sevilla (IBiS)</orgName>
								<address>
									<settlement>Seville</settlement>
									<country key="ES">Spain</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName><forename type="first">L</forename><surname>Leibovici</surname></persName>
						</author>
						<author>
							<affiliation key="aff7">
								<orgName type="department">Molecular Biology and Microbiology, Biochemistry, Proteomics and Bioinformatics</orgName>
								<orgName type="institution">Case Western Reserve University School of Medicine</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff9">
								<orgName type="department">Department of Veterans Affairs Medical Center</orgName>
								<address>
									<settlement>Cleveland</settlement>
									<region>OH</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2021-12-16">16 December 2021</date>
						</imprint>
					</monogr>
					<idno type="MD5">2D7DBD87D1DD48ED2AF7295B52545C9D</idno>
					<idno type="DOI">10.1016/j.cmi.2021.11.025</idno>
					<note type="submission">Received 7 August 2021 Received in revised form 28 November 2021 Accepted 29 November 2021</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.1-SNAPSHOT" ident="GROBID" when="2024-05-29T16:55+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>Acinetobacter baumannii Carbapenem-resistant bacteria ESCMID GRADE Multidrug resistant bacteria BSI, bloodstream infection</term>
					<term>CAP, community-acquired pneumonia</term>
					<term>cIAI, complicated intra-abdominal infections</term>
					<term>CRAB, carbapenem-resistant Acinetobacter baumannii</term>
					<term>CRE non-CP, non-carbapenemase-producing carbapenem-resistant Enterobacterales</term>
					<term>CRPA non-MBL, carbapenem-resistant Pseudomonas aeruginosa non-metallo-b-lactamase-producing</term>
					<term>cUTI, complicated urinary tract infections</term>
					<term>EMA, European Medicines Agency</term>
					<term>ESBLs, extended-spectrum b-lactmases</term>
					<term>FDA, US Food and Drug Administration</term>
					<term>HAP, hospital-acquired pneumonia</term>
					<term>MBL, metallo-b-lactamase</term>
					<term>SSTI, skin and soft-tissue infections</term>
					<term>VAP, ventilator-associated pneumonia</term>
				</keywords>
			</textClass>
			<abstract xml:lang="es">
<div xmlns="http://www.tei-c.org/ns/1.0"><p>E. Tacconelli). y Deceased.</p><p>x Mical Paul and Elena Carrara made equal contributions to these guidelines; Evelina Tacconelli and Jesús Rodríguez-Baño made equal contributions to these guidelines.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>According to estimates from the European Center of Disease and Control (ECDC), antibiotic-resistant bacteria caused 600 000 infections and 27 000 attributable deaths in 2015 in Europe <ref type="bibr" target="#b0">[2]</ref>. Almost 70% of this disease burden, in terms of both number of cases and attributable deaths, is caused by multi-drug-resistant Gram-negative bacteria (MDR-GNB). Ratios of attributable deaths compared with the non-infected population or with a population infected with susceptible isolates of the same bacteria are positive, with a factor-increase ranging from 1.5 for MDR Pseudomonas aeruginosa to 6.2 for carbapenem-resistant (CR) Klebsiella pneumoniae from 2007 to 2015 <ref type="bibr" target="#b0">[2]</ref>. The substantial burden of disease, together with the paucity of available treatments and slowly progressing antibiotic pipeline have led the World Health Organization to prioritize four MDR-GNB phenotypes as of critical priority for future research and development investments: CR-Acinetobacter baumannii, CR-P. aeruginosa and CR-and third-generation cephalosporin-resistant Enterobacterales <ref type="bibr" target="#b1">[3]</ref>. Since the issuing of the priority list in 2017, five new antibiotics with activity against MDR-GNB were approved by the European Medicines Agency (EMA) and and the US Food and Drug Administration (FDA), none of which has a new mode of action and all followed a fast-track development pathway that is granted to drugs potentially addressing unmet medical needs <ref type="bibr" target="#b2">[4]</ref>.</p><p>In parallel with huge efforts by pharmaceutical companies, and profit and non-profit organizations to promote research and development of new antibiotics, the scientific community and public health agencies are strongly calling for an increasingly parsimonious use of available antibiotics in order to prevent further development of resistance. In this paradoxical scenario prescribing antibiotics for MDR-GNB infections has become a significant challenge for clinicians worldwide, stretched between the well-known limitations of the old drugs, fear of promoting resistance by using the new antibiotics, the paucity of data on the effects of newly developed antibiotics against MDR-GNB and the costs of the new antibiotics <ref type="bibr" target="#b3">[5]</ref>. The objective of these evidence-based guidelines is to provide recommendations for treatment of infections caused by MDR-GNB in hospitalized patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Questions addressed by the guideline</head><p>Target MDR-GNB and the questions addressed were selected by consensus in the first panel meeting. The guidelines address the targeted treatment of infections caused by third-generation cephalosporin-resistant Enterobacterales (3GCephRE), CR Enterobacterales (CRE), CR P. aeruginosa (CRPA) and CR A. baumannii (CRAB). The following questions were addressed. (a) What is the antibiotic of choice for patients infected with the target MDR-GNB? (b) Should combination antibiotic therapy be used for patients infected with the target CR-GNB?</p><p>The recommendations are summarized in Table <ref type="table">1</ref>. The potential in vitro activity of antibiotics reviewed against the target MDR-GNB is provided in Table <ref type="table">2</ref>. In vitro data point to specific antibiotic combinations that are synergistic against specific CR-GNB or prevent resistance emergence. Yet for patient management, evidence from clinical studies is necessary to select the optimal treatment, including both single and combination therapies <ref type="bibr" target="#b4">[6,</ref><ref type="bibr" target="#b5">7]</ref> Therefore, the guidelines are based on a systematic review of clinical evidence. Expected users of these guidelines include both policy-makers and in-hospital antibiotic prescribers, especially infectious disease, clinical microbiology and intensive care specialists. For patients with BSI due to 3GCephRE without septic shock, ertapenem instead of imipenem or meropenem may be used.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conditional Moderate</head><p>For patients with low-risk, non-severe infections due to 3GCephRE, under the consideration of antibiotic stewardship, we suggest piperacillin-tazobactam, amoxicillin/clavulanic acid or quinolones. It may be good practice to consider cotrimoxazole for non-severe cUTI. </p><note type="other">No</note></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Methods</head><p>First, a systematic review was performed to support the recommendations. The certainty of the evidence was classified using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Second, an expert panel translated the evidence to recommendations and the strength of recommendations was adjudicated. Finally, the recommendations were discussed and revised until consensus was achieved and the final list of recommendations was formally approved by the whole panel. The review protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement <ref type="bibr" target="#b6">[8]</ref> and foresaw the inclusion of all studies evaluating the efficacy of any antibiotic regimen on clinical outcomes in hospitalized patients with infections caused by MDR-GNB.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Description of the developing group</head><p>A guideline panel was convened by the ESCMID Executive Committee in 2018. Experts on the management of MDR-GNB infections, bacteriology and mechanisms of resistance were selected from the fields of infectious diseases, clinical microbiology, intensive care and pharmacokinetics-pharmacodynamics, targeting multinational representation. Conflict of interest statements were collected from all panel members before starting and after completion of the guideline development. The guideline development process is further detailed in the Supplementary material (Appendix S1).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Literature search</head><p>Relevant clinical studies were identified through computerized literature searches using PubMed, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, FDA drug approval documents and the panel experts' own studies. Three separate search strategies for each target organism (Acinetobacter, Enterobacterales and P. aeruginosa) were developed through the combination of Medical Subject Headings and equivalent terms and adapted for the different databases (Appendix 1). The last systematic search was conducted in December 2019. After the final search date, studies (including randomized controlled trials from international conferences) having a significant impact on the recommendations were identified by the authors and added, until 12 July (ECCMID) 2021.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Inclusion criteria</head><p>We included comparative randomized controlled trials (RCT) or observational studies (both retrospective or prospective), examining different antibiotic treatment regimens for infections caused by the designated MDR-GNB. Only studies reporting on the defined clinical and/or microbiological outcomes were included. We did not include conference proceedings and excluded case reports, small case series with fewer than ten patients, in vitro and animal studies and studies on prophylaxis or decolonization.</p><p>The guidelines address two main questions on selection of the optimal monotherapy and on monotherapy versus combination therapy for the different MDR-GNB. The questions were posed in the PICO framework (Population/participant, Intervention, Comparator/control, Outcome). The full PICO questions are detailed in the Supplementary material (Appendix S1). In brief, the research questions were formulated as follow:</p><p>Population: Hospitalized patients with infections requiring systemic treatment due to the selected microorganisms (3GCephRE, CRE, CRPA and CRAB). We excluded studies assessing patients with uncomplicated urinary tract infections (UTI) and tracheobronchitis.</p><p>Intervention: Targeted treatment (following pathogen and susceptibility identification) with systemic antibiotics, preferably defined in terms of dosage and duration. We included EMA-or FDAapproved antibiotics, approved for any indication.</p><p>Comparator: Patients receiving another antibiotic/antibiotic scheme. The two comparisons assessed any antibiotic versus different antibiotic/s and monotherapy versus combination therapy.</p><p>Outcomes: The primary outcome considered for all analyses was all-cause mortality, preferably at 30 days. If 30-day data were unavailable, we used the closest defined time-point and if unavailable in-hospital all-cause mortality. Secondary outcomes included clinical failure (or cure), microbiological failure, development of resistance, relapse/recurrence, adverse events and length of hospital stay. All outcomes reported in the studies, of the defined outcomes, were extracted.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Definitions</head><p>Sepsis: We adopted the sepsis-3 definition for sepsis, as severe presentation of infection with life-threatening organ dysfunction caused by a dysregulated host response to infection <ref type="bibr" target="#b7">[9]</ref>.</p><p>Septic shock: We similarly accept the sepsis-3 definitions for septic shock when the underlying circulatory and cellular/metabolic abnormalities are profound enough to substantially increase mortality <ref type="bibr" target="#b7">[9]</ref>.</p><p>Severe infections: sepsis or septic shock.</p><p>Low and high-risk infections: Based on the INCREMENT score, we defined infections (including bloodstream infections (BSI)) originating from a urinary tract source of infection or biliary infections after source control as infections at low risk for mortality and other infections as high-risk infections <ref type="bibr" target="#b8">[10,</ref><ref type="bibr" target="#b9">11]</ref>.</p><p>New antibiotics: Antibiotics approved after 2010. Uncomplicated UTI: Infection causing local bladder signs and symptoms, without fever, other signs of systemic infection, or findings suggestive of kidney involvement.</p><p>Difficult to treat resistance (DTR): Resistance to all b-lactams, including carbapenems, b-lactamase inhibitor combinations and fluoroquinolones <ref type="bibr" target="#b10">[12]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Risk of bias assessment</head><p>Risk of bias assessment was performed for each study by two reviewers independently using adapted versions of the Effective Practice and Organization of Care guidelines for RCT and the NewcastleeOttawa Scale for non-randomized studies <ref type="bibr" target="#b11">[13,</ref><ref type="bibr" target="#b12">14]</ref> Individual studies were classified overall as providing low, moderate or high risk of bias evidence.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review procedures and data extraction</head><p>All articles identified by the search were screened on the basis of the abstract against eligibility criteria and non-relevant documents or duplicates were excluded. Full texts of potentially eligible articles were then assessed by two reviewers independently who applied eligibility criteria. Relevant data were extracted into a pre-defined database. Data extraction and risk of bias assessment were performed independently by two reviewers among the guideline expert panel and discrepancies were resolved through discussion between the two reviewers and, if necessary, with the guideline expert panel. All and only panel members participated in the eligibility assessment and data extraction.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Data synthesis and development of recommendations</head><p>Because of the large, expected heterogeneity of study designs, treatment schemes, patient populations and resistance definitions the expert panel agreed not to perform quantitative synthesis of the data using meta-analysis and results were summarized qualitatively. When possible, recommendations tried to address severe infections versus others, at-risk infection sources versus others and different mechanisms of resistance. Available evidence for each treatment comparison was classified by the panel following the GRADE system <ref type="bibr" target="#b13">[15]</ref>. Certainty of the evidence was classified as high, moderate, low or very low. Recommendations were classified as strong or conditional (weak). When no evidence was available, good practice statements were designated based on expert opinion. All recommendations are conditional on the in vitro activity of the recommended antibiotics.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1.">Third-generation cephalosporin-resistant Enterobacterales</head><p>Question 1.1: What is the antibiotic of choice for 3GCephRE</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>For patients with BSI and severe infection due to 3GCephRE, we recommend a carbapenem (imipenem or meropenem) as targeted therapy (strong recommendation for use, moderate certainty of evidence). For patients with BSI due to 3GCephRE without septic shock, ertapenem instead of imipenem or meropenem may be used (conditional recommendation for use, moderate certainty of evidence). For patients with low-risk, non-severe infections due to 3GCephRE, under the consideration of antibiotic stewardship, we suggest piperacillin-tazobactam, amoxicillin/clavulanic acid or quinolones (conditional recommendation for use, moderate certainty of evidence/good practice statement). It may be good practice to consider cotrimoxazole for non-severe complicated UTI (cUTI) (good practice statement). For cUTI in patients without septic shock, we conditionally recommend aminoglycosides when active in vitro, for short durations of therapy (conditional recommendation for use, moderate certainty of evidence), or intravenous fosfomycin (strong recommendation for use, high certainty of evidence) Among all patients with 3GCephRE infections, stepdown targeted therapy following carbapenems once patients are stabilized, using old b-lactam/b-lactamase inhibitors (BLBLI), quinolones, cotrimoxazole or other antibiotics based on the susceptibility pattern of the isolate, is good clinical practice (good practice statement). We do not recommend tigecycline for infections caused by 3GCephRE (strong recommendation against use, very low certainty of evidence). Among all patients with 3GCephRE infections, the new BLBLI are reserve antibiotics for extensively resistant bacteria and therefore, we consider it good clinical practice to avoid their use for infections caused by 3GCephRE, due to antibiotic stewardship considerations (good practice statement). We suggest that cephamycins (e.g. cefoxitin, cefmetazole, flomoxef) and cefepime not be used for 3GCephRE infections (conditional recommendation against use, very low certainty of evidence). For cefoperazone-sulbactam, ampicillin-sulbactam, ticarcillinclavulanic acid, temocillin and mecillinam there is insufficient evidence for the management of patients with 3GCephRE infections at the time of writing and therefore no recommendation can be issued.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>The data available on 3GCephRE are derived mainly from observational studies in the hospital setting including patients with BSI and urinary source of infection. In many studies there was a lack of information on the bacterial species and mechanisms of resistance. Extended-spectrum b-lactamase (ESBL) production was the most commonly reported resistance mechanism, mostly without specifying the type of b-lactamases conferring the ESBL phenotype.</p><p>The main comparison is between the older BLBLI (amoxicillinclavulanate and piperacillin-tazobactam) and carbapenems and discusses the conflict between the MERINO RCT <ref type="bibr" target="#b14">[16]</ref> and the observational data <ref type="bibr" target="#b15">[17,</ref><ref type="bibr" target="#b16">18]</ref>. An underlying stewardship consideration for this comparison was the association between carbapenem use and CRE <ref type="bibr" target="#b17">[19]</ref>. Data on new antibiotics are sparse because most new antibiotic approval RCT were syndrome-based and the subgroups of patients with 3GCephRE infections were small. For 3GcephRE, only PICO 1 on the choice of antibiotic treatment was addressed.</p><p>The evidence on treatment of infections caused by 3GCephRE is provided by clinical syndrome: BSI, UTI, pneumonia and intraabdominal infection (IAI). All studies referred to in the text are described in Table <ref type="table" target="#tab_2">3</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Bloodstream infections</head><p>BLBLI versus carbapenems. The MERINO trial compared piperacillin-tazobactam with meropenem among patients with BSI caused by third-generation cephalosporin-resistant Escherichia coli and K. pneumoniae <ref type="bibr" target="#b14">[16]</ref>. The primary outcome was 30-day mortality and the study did not prove the non-inferiority of piperacillintazobactam, with 30-day mortality rates of 23/187 (12.3%) with piperacillin-tazobactam versus 7/191 (3.7%) with meropenem (risk difference (RD) 8.6%, one-sided 97.5% CI e∞ to 14.5%). The risk difference was lower in the subgroup of patients with UTI (RD 3.7%, e∞ to 10.7%) than among patients with other sources of BSI (RD 14.1%, e∞ to 24.5%). Following the trial, the authors found a high rate of false susceptibility to piperacillin-tazobactam among OXA-1 producers with automatic methods or strip-gradient tests performed in the trial sites. A further analysis of the trial excluded patients with BSI caused by non-susceptible strains (piperacillintazobactam MIC &gt;16 mg/L; meropenem MIC &gt;1 mg/L CLSI, or MIC &gt;2 mg/L EUCAST), as assessed by broth microdilution in a reference laboratory <ref type="bibr" target="#b18">[20]</ref> The difference between groups decreased and was non-significant with a smaller sample size, mortality 13/134 (9.7%) with piperacillin-tazobactam versus 6/149 (4%) with meropenem, risk difference 5.7% (95% CI e1% to 11%). The certainty from this trial showing advantage of meropenem compared with piperacillintazobactam was classified as moderate, due to indirectness related to the high rate of OXA-1-producers with high MICs to piperacillintazobactam and to the small sample size of the further subgroup analyses. The MERINO-2 was a pilot RCT comparing piperacillintazobactam and meropenem among patients with BSI caused by presumed Amp-C b-lactamase-producing but third-generation cephalosporin-susceptible Enterobacter spp., Citrobacter freundii, Morganella morganii, Providencia spp., Klebsiella aerogenes or Serratia marcescens <ref type="bibr" target="#b19">[21]</ref>. Among 70 included patients, mortality was very low (two patients in the meropenem arm) and there was no significant difference in clinical failure (8/38, 21% with piperacillintazobactam versus 4/34, 12% with meropenem).</p><p>A large number of observational studies compared carbapenem therapy with old BLBLI for the therapy of 3GCephRE BSI (20 studies, Table <ref type="table" target="#tab_2">3</ref>) [22e41]. Empirical and targeted therapies were assessed in about half of the studies each, and all reported on mortality,  variably reporting also secondary outcomes. The largest study included 365 patients for the empirical treatment and 601 patients for targeted treatment <ref type="bibr" target="#b20">[22]</ref>, but most included a few dozen patients (Table <ref type="table" target="#tab_2">3</ref>). None of the studies showed a significant difference between groups, except for a small study at high risk of bias showing higher unadjusted mortality with BLBLI including all Enterobacterales <ref type="bibr" target="#b39">[41]</ref>. None of the studies were at low risk of bias; 13 were classified at moderate risk, when using an adjusted analysis with a minimal sample size allowing some adjustment and seven at high risk, mostly reporting crude associations. Hence, there is a large bulk of observational, real-life, data showing no differences in mortality and other outcomes between BLBLI and carbapenems for the treatment for 3GCephRE BSI. These data are highly limited by small samples sizes that do not allow for full adjustment for indication bias, severity of infection, different bacteria and ESBL types, sources of infection and the interaction between types of bacteria and source of infection. Different susceptibility testing methods and definitions of 3GCephRE were used in different studies. The overall certainty of the evidence for the lack of advantage for carbapenems from observational studies was judged as low for lowrisk BSI, and very low for high-risk BSI.</p><p>Carbapenems versus non-carbapenems and BLBLI versus non-BLBLI. Nine retrospective observational studies compared carbapenems with any other non-carbapenem antibiotic (carbapenemsparing regimen); two addressed empirical treatments and all but one analysed the targeted treatment phase <ref type="bibr">[30,42e49]</ref>. The carbapenem-sparing regimens included mainly BLBLI, quinolones and aminoglycosides. Four studies reported an adjusted association and none of these found a significant outcome difference between carbapenems and non-carbapenems, but the sample sizes were small and residual differences between groups remained despite adjustment (moderate-risk to high-risk bias) <ref type="bibr">[43,47e49]</ref>. Odds ratios for mortality tended in favour of carbapenems in two studies <ref type="bibr" target="#b41">[43,</ref><ref type="bibr" target="#b47">49]</ref>, clinical failure was in favour of non-intravenous carbapenem-sparing antibiotics in one <ref type="bibr" target="#b45">[47]</ref> and in the largest study (249 patients receiving empirical carbapenems compared with 86 patients receiving mainly aminoglycosides), there was no significant difference between groups with respect to mortality and clinical failure <ref type="bibr" target="#b46">[48]</ref>.</p><p>Three studies compared old BLBLI with a comparator regimen <ref type="bibr" target="#b25">[27,</ref><ref type="bibr" target="#b40">42,</ref><ref type="bibr" target="#b44">46]</ref>. A single study using propensity score matching showed numerically better outcomes with a carbapenem or cefepime compared with piperacillin-tazobactam as targeted treatment for AmpC-b-lactamase-producing Enterobacterales, but with a small sample and no statistically significant difference between groups <ref type="bibr" target="#b25">[27]</ref>. All studies were at high risk of bias precluding inferences for this comparison. This is a small body of observational evidence further supporting no significant advantage to carbapenems in the real-life treatment of 3GCephRE BSI, but the certainty of this evidence is very low.</p><p>Ertapenem versus imipenem/meropenem. Four observational studies [50e53] and one small RCT <ref type="bibr" target="#b52">[54]</ref> compared ertapenem with imipenem or meropenem, mostly as targeted therapy for BSI caused by any Enterobacterales. The studies included BSI of different sources, with UTI comprising 40%e47% of the patients in all studies. The RCT included also non-bacteraemic infections and found significantly lower mortality with ertapenem <ref type="bibr" target="#b52">[54]</ref>. The other studies did not find a significant difference between the different carbapenems. Although most reported an adjusted analysis, the risk of bias was moderate to high because there was a large difference between groups at baseline, with ertapenem used for less severe infections or prescribed as de-escalation therapy after clinical improvement in studies evaluating targeted therapy. The overall certainty of the evidence showing similar or better  <ref type="bibr" target="#b70">[72]</ref>  outcomes for ertapenem and imipenem/meropenem for 3GCephRE BSI was moderate.</p><p>Cephamycins and cefepime. Cephamycins may be active against ESBL-producing 3GcephRE. Five retrospective observational cohort studies evaluated cefmetazole or flomoxef versus carbapenems for 3GCephRE BSI (27 to 389 patients per study) [55e59]. All evaluated mortality. In the largest study including 389 patients, overall, no association was found between targeted flomoxef therapy and mortality; but when flomoxef's MIC were elevated within the susceptible range (2e8 mg/L), flomoxef was associated with mortality compared with carbapenems (adjusted OR 5.7; 95% CI 1.9e16.8) <ref type="bibr" target="#b55">[57]</ref>. Another small study of 42 patients with dialysis access-related ESBL-Klebsiella spp. BSI showed higher mortality with targeted flomoxef compared with carbapenems, but most patients did not receive in vitro covering therapy in the first 5 days and appropriate adjustment was not possible considering the sample size <ref type="bibr" target="#b54">[56]</ref>. The overall certainty of the evidence for a possible advantage of carbapenems over cephamycins was very low.</p><p>Cefepime may be active against AmpC-producing 3GcephRE. Seven retrospective observational cohort studies evaluated cefepime versus carbapenems [60e65] or a non-cefepime regimen <ref type="bibr" target="#b41">[43]</ref>. Variation in results depending on resistance mechanism was found, with higher mortality sometimes reported with cefepime for ESBL infections and no difference in outcomes in studies specifically addressing AmpC producers. Two studies from the same group in Taiwan found an association between cefepime treatment and mortality <ref type="bibr" target="#b58">[60,</ref><ref type="bibr" target="#b61">63]</ref>. In a study including 144 patients with cephalosporin-resistant Enterobacter spp. infections, overall there was no significant association, but in a very small subgroup of patients with higher cefepime MIC in the susceptible dose-dependent category, mortality was higher with cefepime (5 of 7 versus 2 of 11, p 0.045) <ref type="bibr" target="#b61">[63]</ref>. In a study of 178 patients with ESBL-producing Enterobacterales BSI, definitive treatment with cefepime administered only to 17 patients was associated with higher mortality both in multivariate analysis and a propensity-score matched analysis <ref type="bibr" target="#b58">[60]</ref>. The other studies were smaller and found no significant difference between cefepime and carbapenems or comparator antibiotics. Most studies were at high risk of bias and, considering serious inconsistency, there was very low certainty of evidence for no difference between cefepime and carbapenems or inferiority of cefepime with high MIC compared with carbapenems.</p><p>Other antibiotics. Quinolones were examined individually <ref type="bibr" target="#b40">[42,</ref><ref type="bibr" target="#b64">66,</ref><ref type="bibr" target="#b65">67]</ref> or as part of a general comparator group <ref type="bibr" target="#b43">[45]</ref> in five retrospective cohort studies. In a single study reporting an adjusted analysis for mortality with targeted quinolone treatment (24 patients) compared with carbapenems, quinolone treatment was associated with lower mortality <ref type="bibr" target="#b65">[67]</ref>. The quinolone group in all studies was very small (4e24 patients) and this analysis is a priori very difficult to analyse in an observational design, because quinolones, administered orally with good bioavailability, were given as stepdown therapy to stable patients. As a result, there is no direct evidence on targeted quinolone therapy for 3GcephRE BSI, but favourable effects were observed in studies assessing Gram-negative bacteraemia in general, where a proportion of patients is expected to have had 3GcephRE BSI <ref type="bibr" target="#b66">[68]</ref>.</p><p>Aminoglycosides were examined specifically in a single study <ref type="bibr" target="#b67">[69]</ref> and as part of a general comparator group in two studies <ref type="bibr" target="#b40">[42,</ref><ref type="bibr" target="#b68">70]</ref>. In the single study reporting an adjusted analysis (moderate risk of bias), aminoglycosides as targeted therapy for BSI of urinary tract source were not significantly different from carbapenems or piperacillin-tazobactam, but with large confidence intervals <ref type="bibr" target="#b67">[69]</ref>. Given the paucity of data and observational design, there is very-low-certainty evidence for aminoglycoside treatment for bacteraemic UTI.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Complicated urinary tract infections with or without bacteraemia.</head><p>Intravenous fosfomycin was compared with piperacillin-tazobactam (ZEUS <ref type="bibr" target="#b69">[71]</ref>) or meropenem (FOREST <ref type="bibr" target="#b70">[72]</ref>) in two RCT. The ZEUS trial included patients with cUTI or acute pyelonephritis, including few patients with BSI, and the FOREST trial included patients with bacteraemic cUTI caused by E. coli. Both trials showed no significant differences in clinical or microbiological cure between intravenous fosfomycin and comparators in the subgroup of patients with cephalosporin-resistant or ESBL-producing Enterobacterales. In the FOREST trial, 6/70 (8.6%) patients in the intravenous fosfomycin arm developed heart failure (compared with 1/ 73 with meropenem). The trials were not powered to show noninferiority in this subgroup, but together provide high-certainty evidence for treatment of cUTI with intravenous fosfomycin, in patients without septic shock, with or without bacteraemia. Safety should be considered among patients at risk for heart failure. Oral fosfomycin was compared with ertapenem for oral stepdown or outpatient therapy in an observational study in patients with mostly complicated non-bacteraemic UTI caused by ESBL-producing Enterobacterales <ref type="bibr" target="#b71">[73]</ref>. The study was at high risk of bias due to the large baseline differences between groups and did not reveal a significant difference between 89 patients treated with fosfomycin and 89 treated with ertapenem (very low certainty of evidence).</p><p>Plazomicin was not significantly different from meropenem in a subgroup analysis of an RCT including cUTI caused by 3GCephRE Enterobacterales and reporting on microbiological cure, but with broad confidence intervals (risk difference 7.4, 95% CI À9.6 to 23.1, low risk of bias) <ref type="bibr" target="#b72">[74]</ref>. Together with the retrospective cohort study finding no significant advantage in mortality or relapse for carbapenem or piperacillin-tazobactam over aminoglycosides given as targeted treatment for bacteraemic UTI (moderate risk of bias) <ref type="bibr" target="#b67">[69]</ref>, there was moderate-certainty evidence for aminoglycoside treatment of cUTI. The risk for nephrotoxicity increases after 7 days of aminoglycoside therapy <ref type="bibr" target="#b73">[75]</ref>, so shorter durations are recommended.</p><p>Other carbapenem-sparing treatments were evaluated in several studies. Carbapenems versus BLBLI were evaluated in one RCT <ref type="bibr" target="#b30">[32]</ref> at high risk of bias due to small sample size and baseline differences between groups and several observational studies (moderate to high risk of bias) <ref type="bibr" target="#b26">[28,</ref><ref type="bibr" target="#b31">33,</ref><ref type="bibr" target="#b33">35]</ref>. All studies evaluated the targeted treatment of pyelonephritis and assessed variable clinical and microbiological cure and mortality; one study assessed relapse and resistance selection <ref type="bibr" target="#b33">[35]</ref>. None of the studies found statistically significant differences between BLBLI and carbapenems, supporting moderate-certainty evidence for BLBLI in the treatment of pyelonephritis caused by 3GCephRE.</p><p>Cephamycins and cefepime were compared with carbapenems in several retrospective cohort studies [76e79]. None found statistically significant differences between groups, in very small sample sizes (the cephalosporin group ranging from 10 to 23 patients). All studies were at high risk of bias, together providing lowcertainty evidence for cephamycins and cefepime for the treatment of pyelonephritis caused by 3GCephRE.</p><p>Temocillin provided for more than 50% of the time of effective antibiotic therapy duration was compared with carbapenems in a matched caseecontrol study (144 patients) <ref type="bibr" target="#b78">[80]</ref>. The study showed no significant difference between treatment groups in clinical cure, relapse and mortality, but despite matching there were significant differences between groups that were not adjusted for, and the confidence intervals were large, providing very low-certainty evidence for temocillin in cUTI.</p><p>Finally, two retrospective studies did not reveal significant differences in clinical cure and microbiological outcomes between carbapenems and any non-carbapenem antibiotic, with high risk of bias <ref type="bibr" target="#b79">[81,</ref><ref type="bibr" target="#b80">82]</ref>. Different carbapenem-sparing options, mainly BLBLI, were found to achieve similar outcomes to carbapenems in the treatment of complicated UTI (moderate-certainty evidence).</p><p>Antibiotic approval RCT compared ceftazidime-avibactam with carbapenems or best available therapy in subgroup analyses of 3GCephRE UTI [83e85]. They showed no significant differences between groups in clinical failure, with an advantage to ceftazidime-avibactam in microbiological cure in one trial (high certainty of evidence) <ref type="bibr" target="#b82">[84]</ref>. Ceftolozane-tazobactam was evaluated in a subgroup analysis of an RCT compared with levofloxacin (118 patients) <ref type="bibr" target="#b84">[86]</ref>. An advantage to ceftolozane-tazobactam in clinical cure was observed but was at high risk of bias because resistance to levofloxacin was high (26.7% <ref type="bibr">(195/731</ref>) of all Gram-negatives in the trial). However, ceftazidime-avibactam and ceftolozane-tazobactam are not antibiotics of primary interest for the management of UTI and their use should be reserved for extremely drug resistant (XDR) infections such as CR-GNB.</p><p>Hospital-acquired and ventilator-associated pneumonia. Several RCT that included patients with hospital-acquired/ventilator-associated pneumonia (HAP/VAP) reported on subgroup analyses of patients with pneumonia caused by 3GCephRE, comparing imipenem and tigecycline (41 patients overall) <ref type="bibr" target="#b85">[87]</ref>, imipenem and cefepime (23 patients) <ref type="bibr" target="#b86">[88]</ref>, meropenem and ceftazidime-avibactam (75 patients) <ref type="bibr" target="#b87">[89]</ref>, and meropenem and ceftolozane-tazobactam (157 patients) <ref type="bibr" target="#b88">[90]</ref>. An additional small retrospective cohort study reporting unadjusted results compared imipenem and cefepime <ref type="bibr" target="#b89">[91]</ref>. The FDA warns against tigecycline for HAP/VAP, although not addressing specifically 3GCephRE <ref type="bibr" target="#b90">[92]</ref>. The evidence was of very low certainty for tigecycline and cefepime, low certainty for ceftazidime-avibactam compared with carbapenems and high certainty for non-inferiority of ceftolozane-tazobactam versus meropenem in the treatment of HAP/VAP caused by 3GCephRE.</p><p>Intra-abdominal infections. Some of the syndrome-directed IAI antibiotic-approval RCT reported on the subgroup of patients with infections caused by 3GCephRE. Ceftazidime-avibactam was compared with meropenem (overall 106 patients with 3GCephRE) <ref type="bibr" target="#b91">[93]</ref> and with best-available therapy (mostly carbapenem, overall 19 patients with 3GCephRE) <ref type="bibr" target="#b82">[84]</ref>; ceftolozane-tazobactam (with metronidazole) was compared with meropenem (50 patients with ESBL-producing Enterobacterales) <ref type="bibr" target="#b92">[94]</ref>; and eravacycline was compared with ertapenem (39 patients with ESBL-producing Enterobacterales) <ref type="bibr" target="#b93">[95]</ref>. Clinical or microbiological outcomes were similar between groups in all studies. These trials, showing noninferiority of the new antibiotics compared with carbapenems, were not powered to prove non-inferiority in the subgroups of patients with 3GCephRE. Hence, there is moderate certainty for ceftazidime-avibactam in the treatment of IAI caused by 3GCephRE and very low certainty of evidence for eravacycline and ceftolozane-tazobactam.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2.">Carbapenem-resistant Enterobacterales</head><p>Question 2.1: What is the antibiotic of choice for CRE</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>For patients with severe infections due to CRE, we suggest meropenem-vaborbactam or ceftazidime-avibactam if active in vitro (conditional recommendation for use, moderate and low certainty of evidence, respectively). For patients with severe infections due to CRE-carrying metallob-lactamases (MBL) and/or resistant to all other antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam, we conditionally recommend treatment with cefiderocol (conditional recommendation for use, low certainty of evidence). For patients with non-severe infections due to CRE, under the consideration of antibiotic stewardship, we consider the use of an old antibiotic, chosen from among the in vitro active on an individual basis and according to the source of infection, as good clinical practice (good practice statement). For patients with cUTI, we suggest aminoglycosides, including plazomicin, over tigecycline (conditional recommendation for use, low certainty of evidence). We suggest that tigecycline not be used for BSI and HAP/VAP; if necessary, in patients with pneumonia, clinicians may use highdose tigecycline (conditional recommendation against use, low certainty of evidence). There is no evidence to recommend for or against the use of imipenem-relebactam and fosfomycin monotherapies for CRE at the time of writing.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Evidence on antibiotic treatment of CRE derives mostly from observational retrospective studies including patients with mixed type of infections, mostly BSI with heterogeneous sources and various degrees of clinical severity. Combination treatments were rarely reported in terms of individual antibiotics, dosage and duration. Criteria for patient enrolment included both phenotypic and genotypic testing, thus leading to the inclusion of strains with various patterns of antimicrobial resistance, ranging from residual susceptibility to carbapenems to pan-resistant strains. Most of the studies included infections caused by KPC-producing K. pneumoniae and very few data were available for OXA-48 producers, MBL non-carbapenemase producers and CRE other than K. pneumoniae. Ceftazidime-avibactam. Ceftazidime-avibactam is active in vitro against Ambler class A (KPC) and certain class D (OXA-48) carbapenemases but is inactive against MBL producers. Evidence for recommending the use of ceftazidime-avibactam over other antibiotics for the treatment of CRE infections relies only on observational studies [96e100]. In a study using inverse probability of treatment weighting for adjustment of the comparison between patients treated with ceftazidime-avibactam versus those treated with colistin (before ceftazidime-avibactam was available) for CRE infections there was an overall probability for a better outcome with ceftazidime-avibactam of 64% (95% CI 57%e71%) <ref type="bibr" target="#b94">[96]</ref>. The study included mainly CR-K. pneumoniae infections, 46% with BSI, and used an ordinal outcomes analysis (DOOR and partial credit) considering survival, discharge to home and renal failure. Concordant results were shown in another cohort of KPC-producing K. pneumoniae BSI from Italy, where patients failing previous treatment were treated with ceftazidime-avibactam-containing regimens, showing higher survival in a propensity-score-adjusted analysis compared with non-ceftazidime-avibactam-based regimens <ref type="bibr" target="#b97">[99]</ref>. Most of patients in both studies received ceftazidimeavibactam in combination with other agents. One study from Saudi Arabia retrospectively collected patients with infections caused by OXA-48 producers, showing no difference in mortality among inpatients treated with ceftazidime-avibactam compared with polymyxin-or tigecycline-containing regimens <ref type="bibr" target="#b98">[100]</ref>.</p><p>Resistance to ceftazidime-avibactam in bla KPC-2 and bla KPC-3 isolates, retaining the MDR phenotype, has been described regardless of previous exposure to ceftazidime-avibactam or during treatment [101e105]. The mechanisms described include increased hydrolysis of ceftazidime and amino acid insertion, substitution or deletion in the U loop of the KPC protein, disrupting the ability of ceftazidime-avibactam to bind at the active site <ref type="bibr" target="#b101">[103,</ref><ref type="bibr" target="#b104">106,</ref><ref type="bibr" target="#b105">107]</ref>. In different studies, emergence of resistance during or following therapy occurred in up to 3.7%e8.1% of ceftazidime-avibactamtreated patients <ref type="bibr" target="#b99">[101,</ref><ref type="bibr" target="#b106">108]</ref>. More recently in Greece, a novel plasmid-borne Vietnamese extended-spectrum b-lactamase (VEB)-25 has been described in ceftazidime-avibactam-resistant CR-K. pneumoniae strains, independent of ceftazidime-avibactam exposure <ref type="bibr" target="#b107">[109]</ref>. VEB-25 seemed to decrease avibactam's ability to reduce ceftazidime's MIC. In an outbreak including eight patients with ceftazidime-avibactam-resistant KPC-2-producing K. pneumoniae ST-147 in two Greek intensive care units (ICU), horizontal transmission was suspected <ref type="bibr" target="#b108">[110]</ref>.</p><p>Given the observational study designs, the focus on K. pneumoniae and the combination treatments used, there is low-certainty evidence of an advantage of ceftazidime-avibactam over polymyxins for CRE susceptible to ceftazidime-avibactam.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Meropenem-vaborbactam.</head><p>Vaborbactam is a novel cyclic boronic acid inhibitor that restores meropenem activity against producers of numerous class A and C b-lactamases, but it is inactive against MBL and OXA-48 producers <ref type="bibr" target="#b109">[111]</ref>. Clinical efficacy of meropenemvaborbactam in patients with infections due to CRE was tested in an RCT (Tango-II) in comparison with best available treatment (BAT) monotherapy or combinations of polymyxins, carbapenems, aminoglycosides or tigecycline; or monotherapy with ceftazidimeavibactam. Forty-seven patients (randomized 2:1) were included in the final analysis and significantly improved cure rates at the end of treatment were found in the meropenem-vaborbactam group (65.6% versus 33.3%, p 0.03) with non-significantly lower 28-day mortality (15.6% (5/32) versus 33.3% (5/15), p 0.2) and lower rates of renal-related adverse events <ref type="bibr" target="#b110">[112]</ref>. Based on this small study, there is moderate-certainty evidence for an advantage of meropenemvaborbactam for susceptible CRE compared with the old antibiotics.</p><p>Imipenem-relebactam. Relebactam produces a dose-dependent synergy with imipenem against CRE producing KPC or combining AmpC or ESBL with reduced permeability, but it is poorly active against OXA-48 producers <ref type="bibr" target="#b111">[113]</ref>. Efficacy and safety of imipenemrelebactam have been proven to be comparable to those of imipenem or piperacillin-tazobactam in RCT enrolling patients with cUTI, cIAI and HAP/VAP; few patients with CR-GNB infections were included in these studies but comparative clinical outcome data for CRE are not available and the numbers are too small for a meaningful analysis [114e117]. A small RCT including 31 patients with CR-GNB infections (RESTORE-IMI 1) compared the efficacy of imipenem-relebactam with the combination of imipenem and colistin; however, only seven patients with CRE infections were included <ref type="bibr" target="#b116">[118]</ref>. Given the paucity of data available for imipenem-relebactam against CRE, we cannot make recommendations on imipenemrelebactam for CRE at this time.</p><p>Cefiderocol. Although non-inferior to carbapenems for UTI and HAP/VAP caused by carbapenem-susceptible GNB <ref type="bibr" target="#b117">[119,</ref><ref type="bibr" target="#b118">120]</ref>, conflicting results were observed in an open-label RCT designed to assess the efficacy of cefiderocol for CR-GNB (CREDIBLE-CR). A total of 150 patients with proven/suspected CR-GNB infections were randomized 2:1 to receive cefiderocol versus BAT (mostly polymyxin-based combination). The trial included mainly patients with HAP/VAP and BSI and was not powered to conduct specific hypothesis testing. Mortality was higher in the cefiderocol arm at 28 days (25/101, 24.8% with cefiderocol versus 9/49, 18.4% with BAT) and at end of follow up (34/101, 33.7% versus 9/49, 18.4%, respectively). Clinical and microbiological efficacies of cefiderocol versus BAT were similar. A subgroup analysis of patients with MBL-producing CR-GNB infections showed statistically non-significant higher cure and microbiological eradication rates for cefiderocol (16 patients) versus BAT (seven patients), but mortality was not shown, and the analysis did not separate CRE from other CR-GNB. A post-hoc analysis by baseline pathogen revealed that the mortality difference was observed among patients with CRAB infections, but among patients with CR-K. pneumoniae, mortality at end of follow up was 6/28 (21.4%) with cefiderocol versus 4/15 (26.7%) for BAT (and 1/6 versus 0/3 for CR-E. coli, respectively) <ref type="bibr" target="#b119">[121]</ref>. Based on these small subgroup analyses, we conclude on low-certainty evidence for non-inferiority of cefiderocol compared with other antibiotics for MBL-producing CRE.</p><p>Aztreonam. There is no clinical experience evaluating the use of aztreonam monotherapy in the treatment of CRE infections. Aztreonam is uniquely active against MBL-producing CRE <ref type="bibr" target="#b120">[122]</ref>, but as monotherapy it does not cover other broad-spectrum b-lactamases or carbapenemases, frequently co-produced by such strains. Aztreonam-avibactam is being tested in phase 3 trials and is not currently considered in our guideline because it has not been FDA/ EMA approved.</p><p>Polymyxin. Comparative data on efficacy of polymyxins versus other antibiotics for the treatment of CRE are difficult to evaluate because of the lack of active comparators, concomitant use of other active agents and the frequently suboptimal dosing strategy adopted in the existing studies. Higher mortality among patients with CRE infections was observed with colistin compared with ceftazidime-avibactam in a small retrospective study using inverse probability of treatment weighting adjustment <ref type="bibr" target="#b94">[96]</ref>. Conversely, lower 30-day mortality was shown in critically ill patients with KPC-producing K. pneumoniae infections and septic shock treated with a colistin-containing regimen, compared with colistin-free schemes (hazard ratio (0.21) 95% CI 0.05e0.72) <ref type="bibr" target="#b121">[123]</ref>. However, colistin was administered as part of combination therapy regimens in both studies. Hence, there is no evidence on the comparative efficacy of colistin versus other antibiotics for CRE.</p><p>Aminoglycosides. Two studies from the prospective CRaCKle cohort suggest better clinical outcomes with aminoglycoside-containing regimens compared with tigecycline-containing regimens <ref type="bibr" target="#b122">[124,</ref><ref type="bibr" target="#b123">125]</ref>. Van Duin et al. analysed the results from 157 CR-K. pneumoniae infections with a urinary source (20% severe infections) and recorded better clinical cure when compared with tigecycline-based regimens (adjusted HR 5.19, 95% CI 2.03e14.13), whereas no benefit was observed when compared with colistincontaining regimens (adjusted HR 1.92, 95% CI 0.63e5.76) <ref type="bibr" target="#b123">[125]</ref>. Similarly, Messina et al. observed a higher rate of hospital readmission at 90 days in patients treated with tigecycline-based combinations when compared with aminoglycoside-containing combinations (adjusted HR 4.33, 95% CI 1.67e11.6), in a study where cUTI was the most common source (67% of patients) and 8% of patients were bacteraemic <ref type="bibr" target="#b122">[124]</ref>. Microbiological cure was better with aminoglycosides compared with tigecycline for cUTI in the USA <ref type="bibr" target="#b124">[126]</ref>. Another cohort from Spain describes 50 patients with sepsis due to carbapenem and colistin-resistant K. pneumoniae with a prevalent respiratory source where the use of gentamicin in fully susceptible isolates (MIC 4 mg/L) alone or with tigecycline was associated with significantly higher survival at 30 days (adjusted HR 0.30, 95% CI 0.11e0.84) compared with non-aminoglycoside regimens <ref type="bibr" target="#b125">[127]</ref>. Moreover, in a retrospective cohort of kidney transplant patients, amikacin-containing schemes were associated with clinical success for treatment of mixed infections caused by carbapenem-and polymyxin-resistant Enterobacterales (adjusted OR 0.12, 95% CI 0.02e0.64) <ref type="bibr" target="#b126">[128]</ref>. The certainty of the evidence for an advantage of aminoglycosides over tigecycline for cUTI was judged as moderate, with insufficient evidence for other comparisons and other sources of infection.</p><p>Tigecycline. Three studies showed that tigecycline was inferior to aminoglycosides for cUTI caused by CRE (moderate certainty of the evidence) <ref type="bibr">[124e126]</ref>. Two small studies at high risk of bias showed an advantage to polymyxin-based regimens compared with tigecycline-based regimens for CRE BSI <ref type="bibr" target="#b127">[129,</ref><ref type="bibr" target="#b128">130]</ref>. Finally, out of three additional studies assessing tigecycline or eravacycline for CRE infections of any source [131e133], a single study showed survival advantage to tigecycline compared with colistin-based therapy for CRE and/or CRAB, explained by the higher severity of patients receiving colistin <ref type="bibr" target="#b130">[132]</ref>. Among critically ill patients with MDR-GNB infections treated with different dosages of tigecycline, the only independent predictor of clinical cure was the use of high tigecycline dose in the subgroup of patients with VAP <ref type="bibr" target="#b132">[134]</ref>. However, more than 80% of patients in this study received concomitant active antibiotics. A higher dosage of tigecycline (200 mg loading dose followed by 100 mg twice a day) in combination with other drugs was associated with non-significantly higher survival rates also in a cohort of 40 KPC-BSI compared with the standard dosage (100 mg loading dose following by 50 mg twice a day) <ref type="bibr" target="#b133">[135]</ref>. Overall, there was low-certainty evidence for the inferiority of tigecycline compared with other antibiotics for cUTI and BSI caused by CRE. There are no studies comparing tigecycline with other antibiotics for HAP/VAP and IAI caused by CRE. If used, high-dosing regimens should be used for HAP/VAP.</p><p>Fosfomycin. Potential efficacy of intravenous fosfomycin for CRE has been described in in vitro studies and small case series with variable clinical response <ref type="bibr">[136e138]</ref>. In a study from China the use of fosfomycin in combination with other antibiotics for treating CRE-BSI was associated with non-significantly higher survival compared with non-fosfomycin-based schemes in an adjusted analysis <ref type="bibr" target="#b137">[139]</ref>. There is no evidence for fosfomycin monotherapy for CRE.</p><p>Trimethoprim-sulfamethoxazole. Within the already mentioned CRaCKle prospective cohort, a small subgroup of patients with trimethoprim-sulfamethoxazole-susceptible CRE infections received trimethoprim-sulfamethoxazole-based schemes with mortality rates comparable to other treatments. However, in three out of four available follow-up cultures, subsequent isolates were found to be resistant to trimethoprim-sulfamethoxazole <ref type="bibr" target="#b138">[140]</ref> trimethoprim-sulfamethoxazole (no evidence for trimethoprimsulfamethoxazole).</p><p>Eravacycline. Eravacycline has an observed two-fold in vitro higher activity compared with tigecycline against Gram-negative bacteria; however no patients with CRE were included in the trials that brought to its approval <ref type="bibr" target="#b93">[95,</ref><ref type="bibr" target="#b139">141]</ref> (no evidence for eravacycline).</p><p>Plazomicin. Efficacy of plazomicin for the treatment of CRE infections was planned to be tested in the CARE-RCT in comparison with colistin (in combination with meropenem or tigecycline, NCT01970371). The sponsor decided to suspend the study after 2 years because of enrolment difficulties. Available results showed that all-cause mortality at 28 days was 8/20 with colistin combination therapy (6/15 with BSI) versus 2/17 with plazomicin combination therapy (1/14 with BSI) <ref type="bibr" target="#b140">[142]</ref>. Currently, there is insufficient evidence on plazomicin compared to colistin for CRE. Question 2.2: Should combination therapy be used for the treatment of CRE?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>For patients with CRE infections susceptible to and treated with ceftazidime-avibactam, meropenem-vaborbactam or cefiderocol, we do not recommend combination therapy (strong recommendation against use, low certainty of evidence) For patients with severe infections caused by CRE carrying MBL and/or resistant to new antibiotic monotherapies, we suggest aztreonam and ceftazidime-avibactam combination therapy (conditional recommendation for use, moderate certainty of evidence). For patients with severe infections caused by CRE susceptible in vitro only to polymyxins, aminoglycosides, tigecycline or fosfomycin, or in the case of non-availability of new BLBLI, we suggest treatment with more than one drug active in vitro (conditional recommendation for use, moderate certainty of evidence).</p><p>No recommendation for or against specific combinations can be provided. We suggest that clinicians avoid carbapenem-based combination therapy for CRE infections (conditional recommendation against use, low certainty of evidence), unless the meropenem MIC is 8 mg/L, where high-dose extended-infusion meropenem may be used as part of combination therapy if the new BLBLI are not used (conditional recommendation for use, low certainty of evidence). In patients with non-severe infections or among patients with low-risk infections, under the consideration of antibiotic stewardship, we consider the use of monotherapy chosen from among the in vitro active old drugs, on an individual basis and according to the source of infection as good clinical practice (good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Thirty-five studies assessed mortality (all-cause at any timepoint) in patients with CRE infections receiving antibiotic combination versus monotherapy and the results are conflicting <ref type="bibr">[97,123,128,130,139,140,143e171]</ref>. Certainty of the evidence was very low because of the observational nature of most of the studies (34 out of 35 studies) and the considerable risk of bias (high in 12 studies; moderate in 14; and low in 9). Most importantly, the study definitions of 'combination therapy' were highly variable, including poorly specified treatment schemes, comprising from two up to five antibiotics with variable in vitro activity and different dosages and durations. Adjustment for relevant confounders was seldom available, mostly because of the very small sample sizes.</p><p>Single versus multiple-covering therapy. In the few available studies with adequate sample size and adjustment for confounders, the evidence seems to favour combination over monotherapy in terms of better clinical outcomes <ref type="bibr" target="#b121">[123,</ref><ref type="bibr" target="#b145">147,</ref><ref type="bibr" target="#b150">152,</ref><ref type="bibr" target="#b157">159,</ref><ref type="bibr" target="#b161">163,</ref><ref type="bibr" target="#b162">164,</ref><ref type="bibr" target="#b170">172,</ref><ref type="bibr" target="#b171">173]</ref>. This advantage emerges mainly in subgroups of patients with more severe disease and when combination is defined as regimens including more than one in vitro active antimicrobial. In a large retrospective cohort study including patients with BSI (N ¼ 447) and non-bacteraemic infections (n ¼ 214) caused by KPC-producing K. pneumoniae in Italy, treatment including two or more in vitro active antibiotics was associated with lower 14-day mortality (OR 0.52, 95% CI 0.35e0.77) <ref type="bibr" target="#b162">[164]</ref>. In the retrospective INCREMENT cohort such combination therapy was associated with lower 30-day mortality among patients with CRE BSI at high risk for death, with an INCRE-MENT score of 8e15 (n ¼ 166; adjusted HR 0.56, 95% CI 0.34e0.91). Among patients with lower INCREMENT scores (n ¼ 177), combination therapy was not associated with survival (adjusted OR 1.21) 95% CI 0.56e2.56) <ref type="bibr" target="#b150">[152]</ref>. Use of two or more in vitro active antibiotics (including colistin, tigecycline, gentamicin, carbapenems, rifampin) was independently associated with 30-day survival in retrospective study including 111 critically ill patients with KPC-producing K. pneumoniae infections and septic shock <ref type="bibr" target="#b121">[123]</ref>. Lower efficacy of a single drug regimen with these drugs has been attributed to the often suboptimal dosage and the unsuitable pharmacokineticsepharmacodynamics profile for some infection sites [174e176]. Unfortunately, none of these studies focused on specific antibiotic combinations, so information on which antimicrobials should be included in the treatment scheme cannot be derived even from higher-certainty evidence. When looking at smaller studies analysing specific drugs, polymyxin and tigecycline seemed the antimicrobials for which the addition of a companion drug seems more advisable <ref type="bibr">[143,146,147,151e153,155e157,160,161,164,167,177,178]</ref>. Due to the high heterogeneity of treatment included, even in smaller studies, no firm conclusions can be drawn on which companion drug should be preferred when prescribing polymyxin and tigecycline, but treatment with more than one in vitro active antibiotic might be beneficial (moderate-certainty evidence).</p><p>Carbapenem combination therapy. The inclusion of a carbapenem in the combination scheme for treating carbapenem-resistant infections has been a long-standing matter of debate. Two investigator-initiated RCT, the AIDA and OVERCOME trials, evaluated the efficacy of colistin monotherapy versus colistin-meropenem combination therapy in patients with severe infections caused by CR-GNB, mainly HAP/VAP and BSI <ref type="bibr" target="#b158">[160,</ref><ref type="bibr" target="#b177">179]</ref>. Subgroup analysis of patients with CRE infections did not show statistically significant differences in 28-day mortality between colistin monotherapy and colistin-carbapenem combination therapy in both trials: 12/34 (35%) versus 8/39 (21%) (p 0.24) in AIDA <ref type="bibr" target="#b158">[160]</ref> and 11/35 (31%) versus 7/36 (19%) (p 0.25) in OVERCOME <ref type="bibr" target="#b177">[179]</ref>, respectively.</p><p>In the retrospective Italian cohort study of patients' BSI and nonbacteraemic infections due to KPC-producing K. pneumoniae, combination therapy including a carbapenem was associated with lower 14-day mortality when the meropenem MIC were 8 mg/L <ref type="bibr" target="#b162">[164]</ref>. A continuation and re-analysis of the same cohort showed a similar association between high-dose carbapenem-containing combinations (6 g/day, 3 hours infusion) and 14-day survival compared with non-carbapenem containing combinations, even when the MICs were higher (!16 mg/L) <ref type="bibr" target="#b178">[180]</ref>.</p><p>We concluded low-certainty evidence for an advantage of highdose extended-infusion meropenem-polymyxin combination therapy over polymyxin monotherapy in the treatment of severe infections caused by CRE, mainly KPC-producing K. pneumoniae. Double-carbapenem combination therapy. The rationale for using double-carbapenem therapy for treating CRE infections is based on the higher affinity of ertapenem for carbapenemases and a hypothesis that consumption of the carbapnemases by ertapenem will allow for the action of the other carbapenem. In vitro data for synergistic interactions are conflicting <ref type="bibr" target="#b179">[181,</ref><ref type="bibr" target="#b180">182]</ref>. Two observational studies from Italy and one from the USA suggested better survival in patients with invasive KPC infections treated with a double carbapenem regimen when compared with other regimens, even with high carbapenem MICs [183e185]. Lack of adjustment for confounders, small sample size and use of other drugs in the combinations made the authors of these studies conclude that, although promising, this option requires further evaluation (Insufficient evidence).</p><p>New antibiotic combination therapies. Five retrospective cohorts enrolled a total of 824 patients from three countries (USA, Spain and Italy) and compared ceftazidime-avibactam in combination with other antibiotics versus ceftazidime-avibactam monotherapy, showing no difference in mortality and clinical failure in mixed infections caused by KPC and OXA-48 producers <ref type="bibr">[99,154,186e188</ref>]. The largest study included 577 patients with KPC-producing K. pneumoniae infections, mostly BSI, in Italy and showed also that prolonged infusion (!3 hours) of ceftazidime-avibactam and appropriate renal adjustment were associated with 30-day survival <ref type="bibr" target="#b186">[188]</ref>, supporting our good practice statement for optimal antibiotic administration schedules.</p><p>Ceftazidime-avibactam in combination with aztreonam is active in vitro against a substantial proportion of MBL producers, for which treatment options are lacking <ref type="bibr" target="#b187">[189,</ref><ref type="bibr" target="#b188">190]</ref>. Following a small case series reporting on patients with MBL-producing CRE treated with ceftazidime-avibactam-aztreonam <ref type="bibr" target="#b189">[191]</ref>, an observational prospective study was conducted including 102 patients with MBLproducing CRE bacteraemia (82 NDM-producing strains and 20 VIM-producing strains) treated with ceftazidime-avibactam in combination with aztreonam compared with other in vitro covering therapies, mostly combinations <ref type="bibr" target="#b190">[192]</ref>. The isolates were mostly non-susceptible to aztreonam alone. Using propensity-scoreadjusted multivariable regression, the study showed a significant independent association between ceftazidime-avibactam-aztreonam and lower 30-day mortality (HR 0.37, 95% CI 0.13e0.74), clinical failure and length of hospital stay, providing moderatecertainty evidence for ceftazidime-avibactam in combination with aztreonam against BSI caused by MBL-producing CRE susceptible to the combination. There are currently no standardized antimicrobial susceptibility testing methods recommended or clinical interpretative breakpoints approved for the combination.</p><p>In the CREDIBLE RCT <ref type="bibr" target="#b119">[121]</ref>, an observational post-hoc comparison between patients receiving cefiderocol monotherapy versus cefiderocol combination therapy, clinical and microbiological cure rates were similar, but results were not presented separately for CRE and mortality data were not available. There are no studies addressing the clinical use in monotherapy versus combination of recently marketed antibiotics with activity against CRE (imipenem-relebactam, meropenem-vaborbactam, eravacycline and plazomicin).</p><p>Despite numerous results of in vitro studies showing reduction in resistance development when polymyxin <ref type="bibr" target="#b5">[7]</ref> and ceftazidimeavibactam <ref type="bibr" target="#b191">[193]</ref> are combined with other antibiotics, these results are not confirmed in clinical studies. In two retrospective cohort studies of 77 and 577 patients with KPC-producing CRE infections treated with ceftazidime-avibactam, development of resistance to ceftazidime-avibactam occurred in 10.4% and 3.8%, respectively, and was not associated with its use as monotherapy or in combination regimens <ref type="bibr" target="#b184">[186]</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.">Carbapenem-resistant Pseudomonas aeruginosa</head><p>Question 3.1: What is the antibiotic of choice for CRPA</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>In patients with severe infections due to DTR-CRPA, we suggest therapy with ceftolozane-tazobactam if active in vitro (conditional recommendation for use, very low certainty of evidence). Insufficient evidence is available for imipenem-relebactam, cefiderocol and ceftazidime-avibactam at this time. In patients with non-severe or low-risk CRPA infections, under the consideration of antibiotic stewardship, we consider it good clinical practice to use the old antibiotics, chosen from among the in vitro active antibiotics on an individual basis and according to the source of infection (good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>The clinical evidence on management of DTR-CRPA is highly limited. Data from RCT for the new BLBLI are limited to small subgroup analyses of the registration trials, some of which are based on single patients There are no comparative RCT data on the effect of ceftolozane-tazobactam on CRPA infections, although this is the intended use of the drug. Overall, there is no high-certainty evidence pointing to a preferred antibiotic treatment for CRPA.</p><p>New BLBLI. Of the potentially active new BLBLI, only imipenemrelebactam has been tested against CR-GNB in an RCT, in the RESTORE-IMI 1 trial. The trial included patients with HAP, VAP, UTI and IAI caused by CR-GNB, of which CRPA was the most common (16/21 patients allocated to imipenem-relebactam and 8/10 allocated to colistin with imipenem). A favourable overall response to treatment at 28 days, with a definition tailored per infection source, was observed in 13/16 with imipenem-relebactam compared with 5/8 with colistin and imipenem, adjusted difference 3.1 (95% CI e19.8 to 38.2) <ref type="bibr" target="#b116">[118]</ref>.</p><p>Of the RCT evaluating ceftolozane-tazobactam, the trial including patients with nosocomial pneumonia (ASPECT-NP) reported clinical cure among 4/10 versus 2/5 patients with XDR-PA treated with ceftolozane-tazobactam versus meropenem, respectively <ref type="bibr" target="#b88">[90]</ref>. Data on CRPA, however, are not available. Treatment with ceftolozane-tazobactam (100 patients) was compared with polymyxins or aminoglycosides (100 patients), among patients with MDR/XDR P. aeruginosa mixed infections (mostly pneumonia) in a retrospective cohort study <ref type="bibr" target="#b192">[194]</ref>. Clinical cure was higher (adjusted OR 2.63, 95% CI 1.31e5.30) and nephrotoxicity was lower (adjusted OR 0.08, 95% CI 0.03e0.22) with ceftolozane-tazobactam. Aminoglycoside/polymyxins were given mostly in combination therapies, patient selection was unclear, baseline difference between groups could not be fully adjusted and data on carbapenem resistance was not provided (high risk of bias).</p><p>Overall, given the paucity of data on effects against CRPA, we conclude on very-low-certainty evidence for non-inferiority of imipenem-relebactam compared with colistin-meropenem combination therapy and superiority of ceftolozane-tazobactam compared with aminoglycoside/polymyxin combination therapies for CRPA infections with no evidence for other new BLBLI.</p><p>Other antibiotics. In the CREDIBLE RCT, mortality at the end of the study was similar for patients with baseline monomicrobial CRPA infections for cefiderocol (2/11 patients) compared with BAT (2/11 patients). Clinical cure (7/12 versus 5/10 patients, respectively) and microbiological persistence (4/12 versus 2/10 patients, respectively) were not different, in very small numbers (very-low-certainty evidence for non-inferiority of cefidrocol compared with BAT).</p><p>A small, retrospective cohort of 49 patients with nosocomial pneumonia, mostly VAP, caused by CRPA intermediately susceptible to doripenem (MIC 4e8 mg/L), in Thailand compared high-dose, 4-hour infusion of doripenem versus colistin, both combined with fosfomycin. Unadjusted all-cause 30-day mortality was not different; 10/24 versus 10/25, respectively, as were clinical and microbiological cure rates <ref type="bibr" target="#b193">[195]</ref>. No clinical comparative studies were found for intravenous fosfomycin or eravacycline.</p><p>A beforeeafter retrospective study compared the nephrotoxicity of colistin and polymyxin B among critically ill patients with severe, at-risk infections, caused by MDR P. aeruginosa (46 patients) and A. baumannii (107 patients), showing higher RIFLE-defined nephrotoxicity with colistin (adjusted HR 2.27, 95% CI 1.35e3.82) <ref type="bibr" target="#b194">[196]</ref>. Question 3.2: Should combination therapy be used for the treatment of CRPA?</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>Lacking evidence, we cannot recommend for or against the use of combination therapy with the new BLBLI (ceftazidime-avibactam and ceftolozane-tazobactam) or cefiderocol for CRPA infections. When treating severe infections caused by CRPA with polymyxins, aminoglycosides, or fosfomycin, we suggest treatment with two in vitro active drugs (conditional recommendation for use, very low certainty of evidence). No recommendation for or against specific combinations can be provided. In patients with non-severe infections or low-risk CRPA infections, under the consideration of antibiotic stewardship, we consider it good clinical practice to use monotherapy chosen from among the drugs active in vitro, on an individual basis and according to the source of infection (good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Similar to the choice of monotherapy, there is a paucity of data on combination therapy for DTR-CRPA.</p><p>Polymyxin-based combination therapy. Both in the AIDA and OVERCOME RCT comparing colistin with colistin-carbapenem therapy for severe infections caused by CR-GNB there were no significant differences in 28-day mortality in the subgroup of patients with P. aeruginosa infections (21 patients in AIDA and 43 in OVERCOME) <ref type="bibr" target="#b158">[160,</ref><ref type="bibr" target="#b177">179]</ref>. In a retrospective study evaluating 114 patients with nosocomial pneumonia, including ventilator-associated pneumonia, with isolation of XDR-P. aeruginosa, colistin given alone or with a non-active antibiotic was associated with higher mortality than colistin combined with another active antibiotic (adjusted OR 6.63, 95% CI 1.99e22.05) <ref type="bibr" target="#b195">[197]</ref>. From other observational studies, the results for the subgroup of patients with CRPA were non-adjusted. In a retrospective study evaluating critically ill patients with mixed infections caused by P. aeruginosa there was no difference in 30-day mortality among patients treated with polymyxin compared with polymyxin and a second in vitro inactive agent, overall; in a small subgroup of patients with XDR-P. aeruginosa, mortality was lower when combinations were used (14/15 dead with monotherapy versus 0/3 with combinations) <ref type="bibr" target="#b196">[198]</ref>. In another retrospective analysis, Falagas et al. assessed clinical cure rates comparing colistin monotherapy with different combinations for mixed infections due to MDR-GN. There was no significant difference in outcomes in a small subgroup of patients with MDR-P. aeruginosa (9/12 were cured with colistin monotherapy compared with 42/56 with combinations) <ref type="bibr" target="#b197">[199]</ref>.</p><p>There was very low-certainty evidence for an advantage of polymyxin combined with another active antibiotic over polymyxin alone or combined with inactive antibiotics. There was low-certainty evidence on the lack of advantage of carbapenem-polymyxin combination therapy compared with polymyxin monotherapy for CRPA.</p><p>Other combination therapy. A cohort study summarized retrospectively outcomes for patients treated with ceftolozane-tazobactam for MDR-or XDR-P. aeruginosa infections. There was no difference in cure, defined as clinical and microbiological cure at day 7, between patients given ceftolozane-tazobactam monotherapy (14/21, 66.7%) and those treated with ceftolozane-tazobactam in combination with colistin or an aminoglycoside (21/35, 60%), without adjustment <ref type="bibr" target="#b198">[200]</ref>. The study found no significant difference in development of resistance to ceftolozane-tazobactam during therapy between monotherapy and combination therapy. Overall, there was no evidence for other combination therapy for CRPA. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Recommendations</head><p>For patients with CRAB susceptible to sulbactam and HAP/VAP, we suggest ampicillin-sulbactam (conditional recommendation, low certainty of evidence).</p><p>For patients with CRAB resistant to sulbactam, a polymyxin or high-dose tigecycline can be used if active in vitro. Lacking evidence, we cannot recommend on the preferred antibiotic. We conditionally recommend against cefiderocol for the treatment of infections caused by CRAB (conditional recommendations against use, low certainty of evidence).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Antibiotics active in vitro against CRAB have been directly compared, mostly in retrospective observational studies. The studies generally addressed all species within the A. baumannii complex, not specifically A. baumannii (genospecies 2 of the Acinetobacter calcoaceticus-A. baumannii complex), because automated detection tests do not discriminate between the different genospecies included in the A. baumannii complex (A. calcoaceticus, A. baumannii, genospecies 3 and genospecies 13TU). The most common infection described with CRAB is pneumonia, frequently VAP. As colistin's concentrations in epithelial lining fluid after intravenous administration are negligible <ref type="bibr" target="#b199">[201,</ref><ref type="bibr" target="#b200">202]</ref>, we were interested in separate assessment of pneumonia and other sources of infection, but the data were insufficient to provide recommendations by source of infection. Of the antibiotics that have been considered to date, EUCAST does not provide breakpoints for sulbactam and tigecycline, for Acinetobacter.</p><p>Polymyxin versus ampicillin-sulbactam. Several small studies compared polymyxins, mostly colistin, with ampicillin-sulbactam. A small RCT using alternation as the randomization method (not true randomization) included 28 patients in ICU with VAP caused by CRAB susceptible to ampicillin-sulbactam and did not find a difference between ampicillin-sulbactam and colistin in mortality, or clinical or microbiological failure <ref type="bibr" target="#b201">[203]</ref>. Nephrotoxicity was more common with colistin without statistical significance. An RCT evaluating 47 ICU patients diagnosed with CRAB VAP compared colistin and sulbactam, both combined with meropenem, with similar results <ref type="bibr" target="#b202">[204]</ref>. A retrospective study including 167 patients with different CRAB infections, mostly in ICU and mostly with primary BSI or pneumonia, compared colistin or polymyxin B with ampicillin-sulbactam, with additional antibiotics not active in vitro in both groups <ref type="bibr" target="#b203">[205]</ref>. Mortality at end of treatment (but not inhospital mortality) was significantly higher in the polymyxin group (adjusted OR 2.07, 95% CI 1.03e4.16). A retrospective cohort study of 98 patients in ICU with CRAB VAP compared low-dose colistin (6 MIU/day) with ampicillin-sulbactam, showing significantly higher all-cause mortality with colistin, higher microbiological failure and no difference in clinical failure <ref type="bibr" target="#b204">[206]</ref>. A small RCT, presented as an interim study, compared colistin with extended infusion ampicillin-sulbactam (6 g intravenous ampicillin-sulbactam 2:1 four times a day) both combined with high-dose levofloxacin for the treatment of A. baumannii VAP in an ICU where all A. baumannii are carbapenem-resistant <ref type="bibr" target="#b205">[207]</ref>. The study showed a large advantage to ampicillin-sulbactam in 14-day and 28-day mortality, clinical response and renal failure (28-day mortality 9/11 with colistin versus 5/12 with ampicillin-sulbactam). None of the studies addressed the comparative rates of resistance development during therapy. Most studies considered isolates with MIC 8/4 mg/L as susceptible to sulbactam. Dosing of ampicillin-sulbactam was quite heterogeneous across studies, ranging from 3 to 16 g/8 h (for ampicillin-sulbactam 2:1). The data support an advantage to ampicillin-sulbactam over polymyxins for CRAB, but the evidence is of low certainty.</p><p>Polymyxin versus tigecycline. Colistin has been compared with tigecycline in four retrospective observational studies. Most included patients in ICU, mainly with pneumonia, and colistin and tigecycline were commonly combined with other antibiotics <ref type="bibr">[132,208e210]</ref>. All studies, except one <ref type="bibr" target="#b130">[132]</ref>, demonstrated higher mortality and lower clinical response with tigecycline monotherapy, although without statistical significance. In one study, microbiological success was significantly better with colistin <ref type="bibr" target="#b208">[210]</ref>. In three studies, nephrotoxicity was more frequent with colistin [208e210]. Low doses of tigecycline were commonly used (50 mg twice a day), while double dosing may be more appropriate <ref type="bibr" target="#b209">[211]</ref>. From these data, no conclusion can be drawn (no evidence). Tigecycline versus sulbactam-based therapy. A comparison between tigecycline and sulbactam has been included in five retrospective cohort studies. A single-centre, hospital-wide, retrospective study in Taiwan included 386 patients and compared tigecycline-based therapy with sulbactam-based therapy for hospital-acquired infections caused by tigecycline and sulbactam-susceptible CRAB, respectively <ref type="bibr" target="#b210">[212]</ref>. Sulbactam was combined with imipenem, and tigecycline was prescribed variably alone or with a carbapenem or another b-lactam. There was no significant difference in 30-day mortality or length of stay, but there was a significantly lower rate of clinical or microbiological failure in the tigecycline-based group. Another single-centre retrospective study in Taiwan included 84 patients with CRAB pneumonia that were matched to a historical cohort of 84 patients treated with sulbactam or ampicillin-sulbactam, mostly given in combination therapies <ref type="bibr" target="#b211">[213]</ref>. Patients with BSI were excluded. There was no statistically significant difference between groups with respect to 30-day mortality or clinical failure, but there was a significant advantage to sulbactam-based therapy in microbiological cure. A multicentre study in Taiwan comparing retrospectively treatment strategies among critically ill patients hospitalized in ICU with CRAB pneumonia, included a comparison between sulbactam-based combination or monotherapy (12 patients) and tigecycline monotherapy (84 patients) <ref type="bibr" target="#b212">[214]</ref>. ICU mortality (adjusted OR 0.12, 95% CI 0.01e1.02) and treatment failure (adjusted OR 0.14, 95% CI 0.04e0.55) were less frequent with sulbactam-based therapy. A single-centrer retrospective study in China included 210 patients with CRAB-BSI, mostly in ICU, comparing cefoperazone-sulbactam to tigecycline, both given mostly in combination with other antibiotics <ref type="bibr" target="#b213">[215]</ref>. The study demonstrated significantly lower 28-day mortality with sulbactam-based treatment (adjusted HR 0.57, 95% CI 0.34e0.94), despite the fact that 80% of the isolates were resistant to sulbactam <ref type="bibr" target="#b213">[215]</ref>. The last study, retrospectively evaluated 274 episodes of MDR-AB-BSI hospital-wide in one centre in China, showing unadjusted lower mortality with cefoperazone-sulbactam-containing regimens compared with tigecycline-based therapy, although non-susceptibility rates to sulbactam were high <ref type="bibr" target="#b214">[216]</ref>. An increased risk of death with tigecycline for HAP, VAP and bacteraemia has been reported, in general, not specifically for CR-GNB <ref type="bibr" target="#b90">[92]</ref>. The data support low-certainty evidence for an advantage of sulbactambased therapy over tigecycline.</p><p>Cefiderocol. Cefiderocol is a novel siderophore cephalosporin whose MIC 90 for A. baumannii is in the range of 1e8 mg. Cefiderocol was compared with BAT for CR-GNB infections in the previously described CREDIBLE RCT <ref type="bibr" target="#b119">[121,</ref><ref type="bibr" target="#b215">217]</ref> Among patients with CRAB infections in the CREDIBLE trial, the 28-day mortality rates were 19/ 39 (49%) in the cefiderocol group (21/42, 50% with CR-Acinetobacter sp.) versus 3/17 (18%) in the BAT group. Overall, in the trial, there was no advantage to cefiderocol with respect to clinical or microbiological eradication. In the APEKS-NP RCT, similar mortality, clinical and microbiological outcomes were documented for cefiderocol versus high-dose extended-infusion meropenem, in the subgroup of 36 patients with pneumonia and A. baumannii species with meropenem MIC &gt;8 mg/mL, evaluated before switching to in vitro covering therapy in the meropenem arm. Given the limited information available to date, we conclude on low-certainty evidence against cefiderocol treatment of CRAB infections.</p><p>Eravacycline. Eravacycline is a novel synthetic (fluorocycline) that has two-to eight-fold lower MICs than tigecycline against CRAB. It was evaluated in two RCT compared with ertapenem and meropenem for cIAI <ref type="bibr" target="#b93">[95,</ref><ref type="bibr" target="#b139">141]</ref> Although potentially active in vitro, no data are available on its clinical efficacy against CRAB infections.</p><p>Other antibiotics. Small retrospective studies evaluated treatment with aminoglycosides <ref type="bibr" target="#b216">[218,</ref><ref type="bibr" target="#b217">219]</ref> and tetracyclines other than tigecycline <ref type="bibr" target="#b216">[218,</ref><ref type="bibr" target="#b218">220]</ref> for infections caused by MDR-GNB and CRAB. These studies are small and show inconclusive data (no evidence). Question 4.2: Should combination therapy be used for the treatment of CRAB? Recommendations For all patients with CRAB infections, we do not recommend polymyxin-meropenem combination therapy (strong recommendation against use; high certainty of evidence) or polymyxin-rifampin combination therapy (strong recommendation against use, moderate certainty of evidence). For patients with severe and high-risk CRAB infections, we suggest combination therapy including two in vitro active antibiotics among the available antibiotics (polymyxin, aminoglycoside, tigecycline, sulbactam combinations) (conditional recommendation for use, very low certainty of evidence). For patients with CRAB infections with a meropenem MIC &lt;8 mg/L, we consider carbapenem combination therapy, using high-dose extended-infusion carbapenem dosing, as good clinical practice (good practice statement).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Review of the evidence</head><p>Combination therapy for CRAB has been suggested based on in vitro studies showing synergistic interactions between polymyxins and meropenem, imipenem, doripenem <ref type="bibr" target="#b5">[7]</ref>, rifampicin <ref type="bibr" target="#b2">[4,</ref><ref type="bibr" target="#b219">221]</ref>, vancomycin <ref type="bibr" target="#b220">[222]</ref> and many antibiotics <ref type="bibr" target="#b221">[223]</ref> and non-antibiotics <ref type="bibr" target="#b222">[224]</ref>. Synergistic combinations might be associated with better survival <ref type="bibr" target="#b223">[225]</ref>, but for clinical adoption specific combination therapies need to be assessed in clinical studies. Most of the data on CRAB rely on low-certainty observational studies, assessing a large number of antibiotic regimens, many times grouped to 'combination therapy' that does not allow the appraisal of specific antibiotics regimens with biological plausibility of a beneficial interaction. We identified 29 studies comparing monotherapy with combination therapy <ref type="bibr">[160,198,199,209,214,215,226e248]</ref>; six of which were RCT <ref type="bibr" target="#b158">[160,</ref><ref type="bibr" target="#b226">228,</ref><ref type="bibr" target="#b234">236,</ref><ref type="bibr" target="#b236">238,</ref><ref type="bibr" target="#b238">240,</ref><ref type="bibr" target="#b243">245]</ref>.</p><p>Colistin-carbapenem combination therapy. The combination of colistin with meropenem was assessed in the previously described AIDA RCT, including 406 patients with CR-GNB overall and among them 312 with CRAB bacteraemia, VAP or hospital-acquired pneumonia <ref type="bibr" target="#b158">[160]</ref>. There was no significant difference between colistin monotherapy and colistin-meropenem with respect to a primary composite outcome of clinical failure at day 14 or 14-day mortality overall in the randomized trial population (relative risk (RR) 0.93, 95% CI 0.83e1.03 for failure and RR 1.03, 95% CI 0.84e1.28 for mortality with colistin monotherapy) and among patients with CRAB (RR 0.97, 95% CI 0.87e1.09 and RR 1.11, 95% CI 0.82e1.52, respectively). A post-hoc analysis of this trial addressed the subgroup of patients with infections caused by CRAB resistant also to colistin by broth microdilution, showing no benefit to the combination over colistin among patients with colistin-resistant CRAB <ref type="bibr" target="#b235">[237]</ref>. The OVERCOME trial was a double-blind RCT comparing colistin monotherapy with colistin-meropenem combination for HAP/VAP and BSI caused by CR-GNB that similarly included mostly patients with CRAB of infections <ref type="bibr" target="#b177">[179]</ref>. Mortality at 28 days was similar for colistin monotherapy 76/165 (46%) and colistin-meropenem 69/163 (42%) (p 0.5).</p><p>Several observational studies, assessing the combination of polymyxins and carbapanems specifically, showed a significant association between use of the combination and survival or clinical cure <ref type="bibr" target="#b196">[198,</ref><ref type="bibr" target="#b233">235,</ref><ref type="bibr" target="#b245">247]</ref> whereas others did not <ref type="bibr" target="#b197">[199,</ref><ref type="bibr" target="#b242">244]</ref>. Many observational studies included patients treated with a polymyxin-carbapenem combination in a larger group of patients treated with different combination therapies. These studies mostly showed an association between combination therapy and survival, compared with polymyxin monotherapy. However, from these studies the effects of a specific combination regimen cannot be assessed.</p><p>The RCT, including a considerable sample of patients with severe, high-risk, infections caused by CRAB, contribute to high-certainty evidence against carbapenem-polymyxin combination therapies for CRAB infections <ref type="bibr" target="#b158">[160,</ref><ref type="bibr" target="#b177">179]</ref>. Acinetobacter baumannii when resistant to carbapenems is typically highly resistant, with MICs &gt;16 mg/L. If isolates with lower MICs to a carbapenem are identified, or should these become prevalent, combination therapy with high-dose carbapenem may be considered, preferably administered through extended or continuous infusion.</p><p>Colistin-rifampin combination therapy. The combination of colistin with rifampin has been assessed in three RCT <ref type="bibr" target="#b236">[238,</ref><ref type="bibr" target="#b238">240,</ref><ref type="bibr" target="#b243">245]</ref>. In the only powered RCT, including 209 patients with CRAB infections, mostly pneumonia, there was no advantage to colistin-rifampin over colistin monotherapy with respect to 30-day mortality <ref type="bibr" target="#b236">[238]</ref> Microbiological cure was higher with combination therapy, but surveillance for continued carriage of CRAB was not conducted. Another small trial included 43 patients in ICU with VAP caused by CRAB, showing no difference between colistin-rifampin and colistin monotherapy with respect to in-hospital mortality and microbiological failure <ref type="bibr" target="#b243">[245]</ref>. The third RCT included only nine patients assessing death, and clinical and microbiological response, but the lack of differences between the groups are not informative in this small sample <ref type="bibr" target="#b238">[240]</ref>. Rifampin was included in a few patients treated with combination therapy in an observational study comparing mixed combinations with polymyxin monotherapy <ref type="bibr" target="#b246">[248]</ref>, showing no significant survival advantage to the combination. Overall, there was moderate certainty evidence against rifampin-colistin combination therapy for CRAB.</p><p>Other combinations. Other combinations have been tested in single studies. Colistin-vancomycin has been assessed in a retrospective observational study among 57 patients in ICU mostly with CRAB pneumonia, compared with colistin monotherapy <ref type="bibr" target="#b237">[239]</ref>. No difference in mortality or length of stay was observed, but there was a significantly higher rate of nephrotoxicity with the combination. In a retrospective study including critically ill patients in ICU treated with colistin-based regimens, colistin-glycopeptide combination therapy in 42 patients was not significantly different from colistin monotherapy administered to 61 patients with respect to 30-day mortality, ICU stay and hospital stay <ref type="bibr" target="#b239">[241]</ref>. The study included a mix of MDR Gram-negative infections, most (59/103) with MDR A. baumannii. Colistin-fosfomycin was compared with colistin monotherapy in a small RCT including 94 patients with infections caused by CRAB, usually resistant to fosfomycin <ref type="bibr" target="#b226">[228]</ref>. There was no significant difference between groups in 30-day mortality or adverse events, but combination resulted in lower microbiological failure. Other observational studies comparing monotherapy (usually colistin) with combination therapy (usually mixed) show conflicting results <ref type="bibr">[198,199,209,214,215,226,227,229e235,243,244,246,247,249,250]</ref>; however, the bulk of the data seem to show no advantage to combination therapy (very-low-certainty evidence).</p><p>Double covering therapy might be considered, provided that the CRAB is susceptible to more than one antibiotic. The combination of colistin and ampicillin-sulbactam versus colistin alone has been assessed in a small RCT including 49 patients in ICU with VAP caused by CRAB susceptible to ampicillin-sulbactam <ref type="bibr" target="#b234">[236]</ref>. There was an advantage to combination therapy with respect to clinical failure, but no difference in 28-day mortality. A systematic review of observational studies showed an association between colistin monotherapy and mortality when compared with potentially double-covering antibiotic combinations (polymyxin, aminoglycoside, tigecycline, sulbactam combinations) <ref type="bibr" target="#b170">[172]</ref>. Very-low-certainty evidence exists for double covering combination therapy for CRAB.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>General practice recommendations and antibiotic stewardship considerations</head><p>Optimal antibiotic dosing schemes should be used, with attention to adverse effects, especially with the old antibioticsdpolymyxins and aminoglycosides (good practice statement). Dosing and mode of administration should be optimized by pathogen and indication, with use of therapeutic drug monitoring whenever available (good practice statement). We recommend referring to EUCAST's recommended dosing (https://www.eucast.org/clinical_breakpoints/). Source control should always be a priority, to optimize outcomes and shorten antibiotic treatment durations. The guidelines do not address allergies to the recommended antibiotics that should be considered before antibiotic prescription. Nebulized antibiotics were not considered in the current guideline but were addressed by an ESCMID position statement <ref type="bibr" target="#b249">[251]</ref>. Testing against the new BLBLI and polymyxins is recommended for CR-GNB that are resistant to all blactams. Follow-up cultures are recommended in case of treatment failure, especially for CR-GNB, to detect resistance development (good practice statement). For pan-resistant CR-GNB, the panel recommends selection of antibiotic treatment with the least resistant antibiotic/s based on MICs relative to the breakpoints, but mainly optimal source control (good practice statement).</p><p>Throughout the current guideline, antibiotic stewardship considerations have been introduced. The most important concern the use of carbapenems for infections caused by 3GcephRE. In different epidemiological settings of cephalosporin resistance in Enterobacterales and prevalence of CR-GNB, the implications of adopting a sweeping practice of carbapenems for all 3GcephRE are variable. We addressed this recommendation by sepsis severity and source of infection, allowing the option of carbapenem-sparing therapy for non-severe infections and low-risk sources of infection, and addressing stepdown therapy. We support antibiotic stewardship considerations when using colistin (a last resort antibiotic for CRAB and MBL-producing Enterobacterales) and the new BLBLI. Many good practice statements are provided in the guidelines, when no evidence is available and clinical practice mandates decisionmaking. Many of them place a high value on antibiotic stewardship considerations and can be tailored locally.</p><p>The current guidelines address antibiotic treatment targeted to specific pathogens. Empirically, before pathogen identification, these pathogens should be targeted among patients considered at high risk for CR-GNB infections. A difficult antibiotic stewardship balance exists between achieving appropriate empirical antibiotic therapy for patients with infections due to CR-GNB and the need to conserve last resort therapies for these bacteria. The empirical treatment phase is relevant to a much larger population than targeted treatment. Local guidelines, guided by the local epidemiology, should address the empirical treatment phase.</p><p>The Infectious Diseases Society of America recently published guidance documents on the treatment of 3GcephRE, CRE, DTR P. aeruginosa and CRAB <ref type="bibr" target="#b250">[252,</ref><ref type="bibr" target="#b251">253]</ref>. The guidance format, intended to address rapidly evolving topics, does not include a systematic review of the literature and does not use the formal GRADE process to appraise the evidence. Recommendations were developed by six infectious diseases specialists and were made also where evidence was lacking, thus addressing more specific scenarios. The paucity of the evidence on the effects of the new BLBLI against MDR-GNB, mainly CR-GNB, as well as antibiotic stewardship considerations (including also settings in which the new BLBLIs are not available) underly the main differences between our guidelines and the Infectious Diseases Society of America guidance. Our guidelines stress the situations where alternatives to carbapenems and the new BLBLI are possible, stratifying patients by sepsis severity and hence the urgency of sepsis control: piperacillin-tazobactam or amoxicillinclavulanate are considered in the treatment of 3GcephRE in our guidelines; aminoglycosides are considered for cUTI; and the scenarios in which sparing of the new BLBLI is possible are presented. Combination therapies are less strongly recommended in our guidelines that address the certainty of the evidence with respect to clinical outcomes.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Considering costs and equity</head><p>Antibiotics, both old and new, are not equally available worldwide. In low-resource settings, costs of the new antibiotics might prohibit their use; and even in other settings costs of the new antibiotics enter the consideration for use. Antibiotics critical to management of the priority pathogens should be defined and more efforts should be implemented to ensure the universal availability of these antibiotics. Differential costs of the new antibiotics for different socio-economic settings will allow better equity of patient management.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Research needs</head><p>Recommendations for further research were not developed formally and were not graded. Most recommendations in the guideline are based on very-low-certainty evidence or no evidence. Only RCT provided high-certainty evidence. RCT are needed that assess patients with infections due to 3GCephRE and CR-GNB; most antibiotic approval trials of the new antibiotics were syndrome-based and included only a few patients with the MDR bacteria for which these antibiotics were developed. Although we intended by protocol to obtain data by source of infection, this was possible only for 3GCephRE and as a result infection source-specific guidance is mostly lacking. Investigator-initiated RCT are needed addressing these gaps. Concomitantly, observational studies can include a broader and larger patient population and with improved methods to reduce bias can portray the real life and support decision-making. Antibiotic treatments addressed as the exposures in existing studies were frequently combined with other antibiotics, switched and crossed; study designs allowing a cleaner assessment of individual antibiotics or specific combinations are needed. Studies addressing targeted treatment should address the empirical antibiotic treatment and report the phenotypic and genetic characterization of the isolated bacteria to direct more individualized treatment. The ecological impact of different treatment strategies should be evaluated.</p><p>Evidence is lacking on the efficacy and safety of oral antibiotics (e.g. pivmecillinam, fosfomycin, amoxicillin/clavulanic acid), for initial treatment of clinically stable patients with UTI or as oral follow up, compared with continued definitive intravenous therapy. Furthermore, more studies are needed to establish optimal dosing regimens (dose, frequency, intermittent or prolonged administration) and treatment durations especially when using blactam antibiotics.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Transparency declaration</head><p>MP has received research grants from Pfizer. PR has sat on the</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>4 .</head><label>4</label><figDesc>Carbapenem-resistant Acinetobacter baumannii Question 4.1: What is the antibiotic of choice for CRAB?</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head></head><label></label><figDesc>Recommendations on the choice of antibiotic treatment for 3GCephREFor patients with BSI and severe infection due to 3GCephRE, we recommend a carbapenem (imipenem or meropenem) as targeted therapy</figDesc><table><row><cell>Table 1</cell><cell></cell><cell></cell></row><row><cell>Summary of recommendations</cell><cell></cell><cell></cell></row><row><cell>Recommendation</cell><cell>Strength of recommendation</cell><cell>Level of evidence</cell></row><row><cell>Third-generation cephalosporin-resistant Enterobacterales (3GCephRE)</cell><cell></cell><cell></cell></row><row><cell></cell><cell>Strong</cell><cell>Moderate</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3</head><label>3</label><figDesc>Studies evaluating the treatment of third-generation cephalosporin-resistant Enterobacterales infections</figDesc><table><row><cell>Author year</cell><cell>Design</cell><cell>Infection/s</cell><cell>Pathogen</cell><cell cols="4">% ICU % UTI % BSI Treatment</cell><cell>Group 1</cell><cell>Group 2</cell><cell>Outcome measured</cell><cell>Statistic used</cell><cell>Effect estimate</cell><cell>CI</cell><cell>CI</cell><cell>Risk</cell></row><row><cell></cell><cell></cell><cell>included</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>phase</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>low</cell><cell>high</cell><cell>of bias</cell></row><row><cell>Zanetti 2003 [88]</cell><cell>Subgroup</cell><cell>HAP</cell><cell>Any GNB</cell><cell>100</cell><cell>0</cell><cell></cell><cell>Any</cell><cell>Cefepime,</cell><cell>Imipenem,</cell><cell>Clinical cure</cell><cell>Crude</cell><cell>9/13 vs. 10/10</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell></cell><cell>analysis of RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 13</cell><cell>n ¼ 10</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Endimiani 2004 [66]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Klebsiella</cell><cell>62</cell><cell></cell><cell>100</cell><cell>Targeted</cell><cell>FQ,</cell><cell>Carbapenem,</cell><cell>Clinical cure</cell><cell>Crude</cell><cell>2/7 vs. 8/10, p 0.03</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell></cell><cell>retrospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 7</cell><cell>n ¼ 10</cell><cell></cell><cell>unadjusted</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Paterson 2004 [254]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Klebsiella</cell><cell>39.4</cell><cell>14.1</cell><cell>100</cell><cell>Targeted</cell><cell>Carbapenem,</cell><cell>Other than</cell><cell>Mortality</cell><cell>OR adjusted</cell><cell>0.28</cell><cell>0.08</cell><cell>1</cell><cell>H</cell></row><row><cell></cell><cell>prospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 42</cell><cell>carbapenem,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 29</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Goethaert 2006 [91]</cell><cell>Cohort</cell><cell>Any, mainly</cell><cell>Enterobacter</cell><cell>100</cell><cell>5</cell><cell cols="2">15.9 Targeted</cell><cell>Cefepime,</cell><cell>Imipenem or</cell><cell>Mortality</cell><cell>Crude</cell><cell>11/21 vs. 8/23, NS</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell></cell><cell>retrospective</cell><cell>pneumonia</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 21</cell><cell>meropenem,</cell><cell></cell><cell>unadjusted</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Goethaert 2006 [91]</cell><cell>Cohort</cell><cell>Any, mainly</cell><cell>Enterobacter</cell><cell>100</cell><cell>5</cell><cell cols="2">15.9 Targeted</cell><cell>Cefepime,</cell><cell>Imipenem or</cell><cell cols="2">Clinical improvement Crude</cell><cell>13/21 vs. 16/23, p 0.59</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell></cell><cell>retrospective</cell><cell>pneumonia</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 21</cell><cell>meropenem,</cell><cell></cell><cell>unadjusted</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Goethaert 2006 [91]</cell><cell>Cohort</cell><cell>Any, mainly</cell><cell>Enterobacter</cell><cell>100</cell><cell>5</cell><cell cols="2">15.9 Targeted</cell><cell>Cefepime,</cell><cell>Imipenem or</cell><cell>Microbiological cure</cell><cell>Crude</cell><cell>5/21 vs. 2/23, p 0.76</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell></cell><cell>retrospective</cell><cell>pneumonia</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 21</cell><cell>meropenem,</cell><cell></cell><cell>unadjusted</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Huang 2006 [45]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Enterobacterales</cell><cell>33.3</cell><cell>20.4</cell><cell>100</cell><cell>Targeted</cell><cell>Non-carbapenems,</cell><cell>Imipenem or</cell><cell>Mortality</cell><cell>Crude</cell><cell>9/32 vs. 2/22, p 0.09</cell><cell></cell><cell></cell><cell>H</cell></row><row><cell>Lee 2006 [55] Chaubey 2010 [42] Chaubey 2010 [42] Chaubey 2010 [42] Chaubey 2010 [42] Chaubey 2010 [42] Freire 2010 [87] Lee 2010 [30] Lee 2011 [53] Chopra 2012 [43]</cell><cell>retrospective Cohort retrospective Cohort retrospective Cohort retrospective Cohort retrospective Cohort retrospective Cohort retrospective Subgroup analysis of RCT Cohort retrospective Cohort retrospective Cohort retrospective</cell><cell>BSI BSI BSI BSI BSI BSI HAP/VAP BSI BSI BSI</cell><cell>Klebsiella E. coli and Klebsiella E. coli and Klebsiella E. coli and Klebsiella E. coli and Klebsiella E. coli and Klebsiella E. coli and Klebsiella Enterobacter E. coli and Klebsiella Enterobacterales</cell><cell>48.1 64.4 25.5</cell><cell>11.1 48 48 48 48 48 0 7.4</cell><cell cols="2">100 100 100 100 100 100 15.4 Any Targeted Any Any Any Any Any 100 Targeted 100 Any 100 Targeted</cell><cell>n ¼ 32 Flomoxef, n ¼ 7 BLBLI, n ¼ 28 Carbapenem, n ¼ 30 FQ, n ¼ 4 Aminoglycosides, n ¼ 10 Sulfamethoxazole, n ¼ 3 Tigecycline, n ¼ 21 Non carbapenems, n ¼ 61 Ertapenem, n ¼ 73 Cefepime, n ¼ 31</cell><cell>meropenem, n ¼ 22 Imipenem or meropenem, n ¼ 20 Other than BLBLI, n ¼ 51 Other than carbapenem, n ¼ 49 Other than FQ, n ¼ 75 Other than aminoglycosides, n ¼ 69 Other than sulfametoxazole, n ¼ 76 Imipenem, n ¼ 20 Carbapenem, n ¼ 53 Imipenem-meropenem, n ¼ 171 Other than cefepime, n ¼ 79</cell><cell>Mortality Mortality Mortality Mortality Mortality Mortality Clinical cure Infection-related mortality Mortality Mortality</cell><cell>unadjusted Crude unadjusted RR unadjusted RR unadjusted RR unadjusted RR unadjusted RR unadjusted Crude Adjusted Crude unadjusted OR adjusted</cell><cell>2/7 vs. 5/20, p 0.86 1.09 0.54 1.25 0.46 1.69 14/21 vs. 19/20, NS Reported as NS, p 0.15 12/73 vs. 30/171, p 1.0 0.8</cell><cell>0.44 0.19 0.22 0.07 0.32 0.34</cell><cell>2.69 1.53 7.24 3.11 8.91 2.29</cell><cell>H H H H H H M H H M</cell><cell>M. Paul et al. / Clinical Microbiology and Infection 28 (2022) 521e547</cell></row><row><cell>Chopra 2012 [43]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Enterobacterales</cell><cell>25.5</cell><cell></cell><cell>100</cell><cell>Targeted</cell><cell>Carbapenem,</cell><cell>Other than</cell><cell>Mortality</cell><cell>OR adjusted</cell><cell>0.5</cell><cell>0.25</cell><cell>1.21</cell><cell>M</cell></row><row><cell></cell><cell>retrospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 78</cell><cell>carbapenem,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 32</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Collins 2012 [50]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Enterobacterales</cell><cell></cell><cell>41.4</cell><cell>100</cell><cell>Empirical</cell><cell>Ertapenem,</cell><cell>Imipenem or</cell><cell>Mortality</cell><cell>OR adjusted</cell><cell>0.82</cell><cell>0.17</cell><cell>3.81</cell><cell>M</cell></row><row><cell></cell><cell>retrospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 24</cell><cell>meropenem,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 103</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Collins 2012 [50]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Enterobacterales</cell><cell></cell><cell>41.4</cell><cell>100</cell><cell>Targeted</cell><cell>Ertapenem,</cell><cell>Imipenem OR</cell><cell>Mortality</cell><cell>OR adjusted</cell><cell>0.5</cell><cell>0.12</cell><cell>2.1</cell><cell>M</cell></row><row><cell></cell><cell>retrospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 72</cell><cell>meropenem,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 132</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rodríguez-Baño 2012</cell><cell>Cohort</cell><cell>BSI</cell><cell>E. coli</cell><cell>12.6</cell><cell>41.9</cell><cell>100</cell><cell>Empirical</cell><cell>BLBLI,</cell><cell>Carbapenem,</cell><cell>Mortality</cell><cell>HR adjusted</cell><cell>0.93</cell><cell>0.25</cell><cell>3.51</cell><cell>M</cell></row><row><cell>[31]</cell><cell>prospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 72</cell><cell>n ¼ 31</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Rodríguez-Baño 2012</cell><cell>Cohort</cell><cell>BSI</cell><cell>E. coli</cell><cell>8.7</cell><cell>41.9</cell><cell>100</cell><cell>Targeted</cell><cell>BLBLI,</cell><cell>Carbapenem,</cell><cell>Mortality</cell><cell>HR adjusted</cell><cell>0.76</cell><cell>0.28</cell><cell>2.07</cell><cell>M</cell></row><row><cell>[31]</cell><cell>prospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 54</cell><cell>n ¼ 120</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Vazquez 2012 [83]</cell><cell>Subgroup</cell><cell>UTI</cell><cell>Enterobacterales</cell><cell></cell><cell>100</cell><cell>7.3</cell><cell>Targeted</cell><cell>Ceftazidime-avibactam,</cell><cell>Imipenem,</cell><cell>Microbiological cure</cell><cell>Crude</cell><cell>6/7 vs. 9/11, NS</cell><cell></cell><cell></cell><cell>L</cell></row><row><cell></cell><cell>analysis of RCT</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 7</cell><cell>n ¼ 11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Wu 2012 [51]</cell><cell>Cohort</cell><cell>BSI</cell><cell>E. coli</cell><cell>16.3</cell><cell>38.8</cell><cell>100</cell><cell>Targeted</cell><cell>Ertapenem,</cell><cell>Imipenem-</cell><cell>Mortality</cell><cell>HR adjusted</cell><cell>0.02</cell><cell>0.001</cell><cell>1.1</cell><cell>H</cell></row><row><cell></cell><cell>prospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 27</cell><cell>meropenem,</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 22</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Yang 2012 [56]</cell><cell>Cohort</cell><cell>BSI</cell><cell>Klebsiella</cell><cell>50.9</cell><cell>0</cell><cell>100</cell><cell>Targeted</cell><cell>Flomoxef,</cell><cell>Carbapenem,</cell><cell>Mortality</cell><cell>OR adjusted</cell><cell>3.52</cell><cell>1.19</cell><cell>58.17</cell><cell>H</cell></row><row><cell></cell><cell>retrospective</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>n ¼ 19</cell><cell>n ¼ 23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell cols="3">(continued on next page)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 3</head><label>3</label><figDesc></figDesc><table><row><cell></cell><cell>Risk</cell><cell>of bias</cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>M</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>M</cell><cell></cell><cell></cell><cell>M</cell><cell></cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>M</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>H</cell><cell></cell><cell>L</cell><cell></cell><cell></cell><cell>M</cell><cell></cell><cell>H</cell><cell></cell><cell></cell><cell>L</cell><cell></cell><cell></cell><cell>L</cell><cell></cell><cell></cell><cell>M</cell><cell></cell><cell>H</cell><cell>H</cell></row><row><cell></cell><cell>CI</cell><cell>high</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>31.91</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.11</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3.19</cell><cell></cell><cell></cell><cell>4.62</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>54.9</cell><cell></cell><cell>6.28</cell><cell></cell><cell></cell><cell></cell><cell>4.2</cell><cell></cell><cell>6.52</cell><cell></cell><cell>4.49</cell><cell></cell><cell>53</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>3.45</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>CI</cell><cell>low</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>2.77</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.23</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.31</cell><cell></cell><cell></cell><cell>0.24</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.35</cell><cell></cell><cell>0.13</cell><cell></cell><cell></cell><cell></cell><cell>0.5</cell><cell></cell><cell>0.11</cell><cell></cell><cell>0.24</cell><cell></cell><cell>1.2</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell>1.07</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell></cell><cell>Effect estimate</cell><cell></cell><cell>9/10 vs. 12/12, p 0.46</cell><cell></cell><cell>0/5 vs. 6/61</cell><cell></cell><cell>9.93</cell><cell></cell><cell>23/23 vs. 4/4</cell><cell></cell><cell>1/23 vs. 0/4</cell><cell></cell><cell>0.63</cell><cell></cell><cell>6/52 vs. 10/91, p 1.0</cell><cell></cell><cell>13/122 vs. 3/21, p 0.626</cell><cell></cell><cell>88% vs. 69%, p 0.138</cell><cell></cell><cell>54.3% vs. 28.5%, p 0.02</cell><cell></cell><cell>15/52 vs. 20/42, p 0.08</cell><cell></cell><cell>0.99</cell><cell></cell><cell></cell><cell>1.05</cell><cell></cell><cell></cell><cell>22/22 vs. 30/31, NS</cell><cell></cell><cell>3/22 vs. 7/31, NS</cell><cell></cell><cell>5/28 vs. 6/32</cell><cell></cell><cell>4.38</cell><cell></cell><cell>0.91</cell><cell></cell><cell>19/72 vs. 16/72, p 0.7</cell><cell></cell><cell>1.4</cell><cell></cell><cell>0.87</cell><cell></cell><cell>1.04</cell><cell></cell><cell>7.9</cell><cell></cell><cell>23/24 (95.8%) vs. 23/26</cell><cell>(88.5%), NS</cell><cell></cell><cell>1.92</cell><cell></cell><cell>55/61 (90.2%) vs. 42/57</cell><cell>(73.7%), difference 16.5%</cell><cell>(95% CI 2.6e30.2)</cell><cell>107/130 (82.3%) vs. 85/</cell><cell>132 (64.4%), p 0.002</cell><cell></cell><cell>120/130 (92.3%) vs. 124/</cell><cell>132 (93.9%), NS</cell><cell></cell><cell>7/9 vs. 5/10, NS</cell><cell></cell><cell>60/60 vs. 170/170, NS</cell><cell>1/26 vs. 5/43</cell></row><row><cell></cell><cell>Statistic used</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Matched</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>HR adjusted</cell><cell></cell><cell></cell><cell>HR adjusted</cell><cell></cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>HR adjusted</cell><cell></cell><cell>Crude unadjusted</cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>HR adjusted</cell><cell></cell><cell>HR adjusted</cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>Crude</cell><cell></cell><cell></cell><cell>OR adjusted</cell><cell></cell><cell>Crude absolute</cell><cell>difference</cell><cell></cell><cell>Crude</cell><cell></cell><cell></cell><cell>Crude</cell><cell></cell><cell></cell><cell>Crude</cell><cell></cell><cell>Crude</cell><cell>unadjusted</cell><cell>Crude</cell><cell>unadjusted</cell></row><row><cell></cell><cell>Outcome measured</cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell>Relapse</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell></cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Microbiological</cell><cell>failure</cell><cell></cell><cell>Clinical failure</cell><cell></cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell>Relapse</cell><cell></cell><cell>Microbiological</cell><cell>cure</cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell></cell><cell>Mortality</cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell></cell><cell>Microbiological cure</cell><cell></cell><cell></cell><cell>Clinical cure</cell><cell></cell><cell></cell><cell>Microbiological cure</cell><cell></cell><cell>Microbiological cure</cell><cell>Mortality</cell></row><row><cell></cell><cell>Group 2</cell><cell></cell><cell>Carbapenem,</cell><cell>n ¼ 12</cell><cell>Carbapenem,</cell><cell>n ¼ 61</cell><cell>Carbapenem,</cell><cell>n ¼ 161</cell><cell>Carbapenem,</cell><cell>n ¼ 4</cell><cell>Carbapenem,</cell><cell>n ¼ 4</cell><cell>Meropenem,</cell><cell>n ¼ 32</cell><cell>Carbapenem,</cell><cell>n ¼ 91</cell><cell>BLBLI,</cell><cell>n ¼ 21</cell><cell>Ertapenem,</cell><cell>n ¼ 16</cell><cell>Carbapenem</cell><cell></cell><cell>Carbapenem,</cell><cell>n ¼ 42</cell><cell>Carbapenems,</cell><cell>n ¼ 85</cell><cell></cell><cell>Carbapenems,</cell><cell>n ¼ 85</cell><cell></cell><cell>Carbapenem,</cell><cell>n ¼ 31</cell><cell>Carbapenem,</cell><cell>n ¼ 31</cell><cell>Carbapenem,</cell><cell>n ¼ 32</cell><cell>Carbapenem,</cell><cell>n ¼ 21</cell><cell>Carbapenem,</cell><cell>n ¼ 23</cell><cell>Carbapenem,</cell><cell>n ¼ 72</cell><cell>Carbapenem,</cell><cell>n ¼ 257</cell><cell>Carbapenem,</cell><cell>n ¼ 45</cell><cell>Carbapenem,</cell><cell>n ¼ 54</cell><cell>Carbapenem,</cell><cell>n ¼ 69</cell><cell>Meropenem,</cell><cell>n ¼ 26</cell><cell></cell><cell>Carbapenem,</cell><cell>n ¼ 110</cell><cell>Levofloxacin,</cell><cell>n ¼ 57</cell><cell></cell><cell>Best available</cell><cell>treatment,</cell><cell>n ¼ 132</cell><cell>Best available</cell><cell>treatment,</cell><cell>n ¼ 132</cell><cell>Best available</cell><cell>treatment,</cell><cell>n ¼ 10</cell><cell>Ertapenem,</cell><cell>n ¼ 170</cell><cell>Carbapenem,</cell><cell>n ¼ 43</cell></row><row><cell></cell><cell>Pathogen % ICU % UTI % BSI Treatment Group 1</cell><cell>phase</cell><cell>Enterobacterales 100 36.3 Targeted Cefmetazole,</cell><cell>n ¼ 10</cell><cell>E. coli 39.1 100 Targeted Aminoglycoside,</cell><cell>n ¼ 5</cell><cell>Enterobacterales 78 100 Targeted Cefepime,</cell><cell>n ¼ 17</cell><cell>Enterobacterales 100 4 Any Non-carbapenems,</cell><cell>n ¼ 23</cell><cell>Enterobacterales 100 4 Any Non-carbapenems,</cell><cell>n ¼ 23</cell><cell>Enterobacterales 57.8 48.7 Targeted Cefepime,</cell><cell>n ¼ 46</cell><cell>E. coli 3.9 43.6 100 Targeted Non-carbapenem,</cell><cell>n ¼ 52</cell><cell>E. coli 3.9 43.6 100 Targeted Non-BLBLI,</cell><cell>n ¼ 122</cell><cell>Enterobacterales 18.7 31.2 20.8 Targeted Cefepime,</cell><cell>n ¼ 32</cell><cell>Enterobacterales 37.2 12.8 100 Targeted Non-carbapenem</cell><cell></cell><cell>Enterobacterales 37.2 12.8 100 Empirical Non-carbapenem,</cell><cell>n ¼ 52</cell><cell>E. coli 13.8 100 34.2 Targeted Non-carbapenem</cell><cell>containing regimen,</cell><cell>n ¼ 67</cell><cell>E. coli 13.8 100 34.2 Targeted Non-carbapenem</cell><cell>containing regimen,</cell><cell>n ¼ 67</cell><cell>Enterobacterales 75.5 24.5 Targeted Non-carbapenem,</cell><cell>n ¼ 22</cell><cell>Enterobacterales 75.5 24.5 Targeted Non-carbapenem,</cell><cell>n ¼ 22</cell><cell>Enterobacter 24 7 100 Empirical Cefepime,</cell><cell>n ¼ 28</cell><cell>Proteus 51.1 100 Not specified Piperacillin-tazobactam,</cell><cell>n ¼ 13</cell><cell>E. coli and Klebsiella 14.9 46.8 100 Targeted BLBLI,</cell><cell>n ¼ 24</cell><cell>Enterobacter 21.9 100 Targeted Cefepime,</cell><cell>n ¼ 72</cell><cell>E. coli and Klebsiella 22.6 100 Targeted Flomoxef,</cell><cell>n ¼ 132</cell><cell>E. coli 52.8 100 Empirical Cefmetazole or flomoxef,</cell><cell>n ¼ 26</cell><cell>E. coli 52.8 100 Targeted Cefmetazole or flomoxef,</cell><cell>n ¼ 59</cell><cell>Enterobacterales 0 100 Targeted Piperacillin-tazobactam,</cell><cell>n ¼ 10</cell><cell>Enterobacterales 0 2.5 Targeted Ceftolozane-tazobactam</cell><cell>þ metronidazole,</cell><cell>n ¼ 24</cell><cell>Enterobacterales 13.8 20.6 100 Empirical Piperacillin-tazobactam,</cell><cell>n ¼ 103</cell><cell>Enterobacterales 100 7.7 Any Ceftolozane-tazobactam,</cell><cell>n ¼ 61</cell><cell></cell><cell>Enterobacterales 100 3.5 Targeted Ceftazidime-avibactam,</cell><cell>n ¼ 130</cell><cell></cell><cell>Enterobacterales 100 3.5 Targeted Ceftazidime-avibactam,</cell><cell>n ¼ 130</cell><cell></cell><cell>Enterobacterales 0 0 Targeted Ceftazidime-avibactam</cell><cell>(þmetronidazole),</cell><cell>n ¼ 9</cell><cell>E. coli and Klebsiella 100 Targeted Piperacillin-tazobactam,</cell><cell>n ¼ 60</cell><cell>Enterobacterales 31.8 50.7 100 Targeted Cefmetazole,</cell><cell>n ¼ 26</cell></row><row><cell></cell><cell>Infection/s</cell><cell>included</cell><cell>UTI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>UTI</cell><cell></cell><cell>UTI</cell><cell></cell><cell>Any</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>Any</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>UTI</cell><cell></cell><cell></cell><cell>UTI</cell><cell></cell><cell></cell><cell>Any</cell><cell></cell><cell>Any</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>BSI</cell><cell></cell><cell>IAI</cell><cell></cell><cell></cell><cell>BSI</cell><cell></cell><cell>UTI</cell><cell></cell><cell></cell><cell>UTI</cell><cell></cell><cell></cell><cell>UTI</cell><cell></cell><cell></cell><cell>IAI</cell><cell></cell><cell>UTI</cell><cell>BSI</cell></row><row><cell>(continued )</cell><cell>Author year Design</cell><cell></cell><cell>Doi 2013 [76] Cohort</cell><cell>retrospective</cell><cell>Kang 2013 [70] Cohort</cell><cell>retrospective</cell><cell>Lee 2013 [81] Cohort</cell><cell>retrospective</cell><cell>Lee 2013 [81] Cohort</cell><cell>retrospective</cell><cell>Lee 2013 [81] Cohort</cell><cell>retrospective</cell><cell>Tamma 2013 [61] Cohort</cell><cell>retrospective</cell><cell>To 2013 [46] Cohort</cell><cell>retrospective</cell><cell>To 2013 [46] Cohort</cell><cell>retrospective</cell><cell>Blanchette 2014 [62] Case-control,</cell><cell>matched</cell><cell>Falcone 2014 [44] Cohort</cell><cell>retrospective</cell><cell>Falcone 2014 [44] Cohort</cell><cell>retrospective</cell><cell>Park 2014 [82] Cohort</cell><cell>retrospective</cell><cell></cell><cell>Park 2014 [82] Cohort</cell><cell>retrospective</cell><cell></cell><cell>Pilmis 2014 [77] Cohort</cell><cell>retrospective</cell><cell>Pilmis 2014 [77] Cohort</cell><cell>retrospective</cell><cell>Siedner 2014 [64] Cohort</cell><cell>retrospective</cell><cell>Tsai 2014 [26] Cohort</cell><cell>retrospective</cell><cell>Harris 2015 [23] Cohort</cell><cell>retrospective</cell><cell>Lee 2015 [63] Cohort</cell><cell>retrospective</cell><cell>Lee 2015 [57] Cohort</cell><cell>retrospective</cell><cell>Matsumura 2015 [58] Cohort</cell><cell>retrospective</cell><cell>Matsumura 2015 [58] Cohort</cell><cell>retrospective</cell><cell>Ofer-Friedman 2015 [41] Cohort</cell><cell>retrospective</cell><cell>Solomkin 2015 [255] Subgroup</cell><cell>analysis of RCT</cell><cell></cell><cell>Tamma 2015 [25] Cohort</cell><cell>retrospective</cell><cell>Wagenlehner 2015 [86] Subgroup</cell><cell>analysis</cell><cell>of RCT</cell><cell>Carmeli 2016 [84] Subgroup</cell><cell>analysis of RCT</cell><cell></cell><cell>Carmeli 2016 [84] Subgroup</cell><cell>analysis of RCT</cell><cell></cell><cell>Carmeli 2016 [84] Subgroup</cell><cell>analysis of RCT</cell><cell>Dizbay 2016 [28] Cohort</cell><cell>retrospective</cell><cell>Fukuchi 2016 [59] Cohort</cell><cell>retrospective</cell></row></table></figure>
		</body>
		<back>

			<div type="acknowledgement">
<div><p>advisory board of <rs type="institution">Shionogi</rs>. RAB has received research grants from <rs type="funder">Merck</rs>, <rs type="funder">Wockhardt</rs>, <rs type="funder">Entasis</rs> and <rs type="funder">Shionogi</rs>. <rs type="person">Jan de Waele</rs> has received honoraria for educational activities from <rs type="funder">MSD</rs> and <rs type="institution">Pfizer</rs>. GLD has received honoraria for educational activities from, consulted for and sat on the advisory board of <rs type="institution">Pfizer</rs>, <rs type="institution">MSD</rs> and <rs type="funder">Shionogi</rs>. MA has received honoraria for educational activities from <rs type="funder">Pfizer</rs>, <rs type="funder">MSD</rs>, <rs type="funder">Gilead</rs> and <rs type="funder">Genentech</rs>, and received research support from <rs type="funder">Pfizer</rs> and <rs type="funder">Gilead</rs>. SH has sat on advisory boards for Sandoz and Bode. JG-M has received honoraria for educational activities from <rs type="funder">Shionogi</rs> and <rs type="institution">Pfizer</rs>. MT has sat on advisory boards for Menarini, <rs type="institution">MSD</rs> and <rs type="funder">Shionogi</rs>, and received honoraria from <rs type="institution">Pfizer</rs>. MB has received honoraria and sat on advisory boards for <rs type="institution">Angelini, Astellas, Bayer, Biom erieux, Cidara</rs>, <rs type="funder">Gilead</rs>, <rs type="funder">Menarini</rs>, <rs type="funder">MSD</rs>, <rs type="funder">Nabriva</rs>, <rs type="funder">Pfizer</rs> and <rs type="funder">Shionogi</rs>. EC, TT, RB, CP, BB, KS, PCL, SG, YY, JWM, ET and JRB have no conflicts of interest to declare.</p></div>
<div><head>Acknowledgements</head><p>We thank the five CMI reviewers and 18 commentators of the ESCMID open consultation who have made a significant contribution to the quality of this guideline.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>These guidelines were supported in part by <rs type="funder">ESCMID</rs>.</p></div>
<div><head>Updating the guideline</head><p>The guidelines will be updated according to ESCMID recommendations.</p></div>
			</div>
			<listOrg type="funding">
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Appendix A. Supplementary data</head><p>Supplementary data to this article can be found online at https://doi.org/10.1016/j.cmi.2021.11.025.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cassini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Hogberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Plachouras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Quattrocchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hoxha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Simonsen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="56" to="e66" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Tacconelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Carrara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Savoldi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harbarth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mendelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Monnet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="318" to="e327" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<monogr>
		<title level="m" type="main">Antibacterial agents in clinical and preclinical development: an overview and analysis</title>
		<ptr target="https://www.who.int/publications/i/item/9789240021303" />
		<imprint>
			<date type="published" when="2020">2020</date>
			<pubPlace>Geneva</pubPlace>
		</imprint>
	</monogr>
	<note>World Health Organization; 2021. Licence: CC BY-NC-SA 3</note>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1733" to="0e819" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli</title>
		<author>
			<persName><forename type="first">L</forename><surname>Scudeller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Righi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chiamenti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bragantini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Menchinelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Cattaneo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page">106344</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zusman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Avni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Leibovici</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Adler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Friberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Stergiopoulou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="5104" to="e5111" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration</title>
		<author>
			<persName><forename type="first">A</forename><surname>Liberati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Altman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tetzlaff</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Mulrow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Gotzsche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Ioannidis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMJ</title>
		<imprint>
			<biblScope unit="volume">339</biblScope>
			<biblScope unit="page">2700</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">The third international consensus definitions for sepsis and septic shock (Sepsis-3)</title>
		<author>
			<persName><forename type="first">M</forename><surname>Singer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Deutschman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Seymour</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Shankar-Hari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Annane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bauer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">315</biblScope>
			<biblScope unit="page" from="801" to="e810" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">A predictive model of mortality in patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salamanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Cueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pano-Pardo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mayo Clin Proc</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="1362" to="1e71" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Development and validation of the INCREMENT-ESBL predictive score for mortality in patients with bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">R</forename><surname>Palacios-Baena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Venditti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hernandez-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="906" to="e913" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Difficult-to-treat resistance in Gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Kadri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Adjemian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Spaulding</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ricotta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Prevots</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="1803" to="e1814" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<monogr>
		<title level="m" type="main">Newcastle-Ottawa quality assessment scale cohort studies</title>
		<author>
			<persName><forename type="first">G</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shea</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Peterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Welch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Losos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2014">2014</date>
		</imprint>
		<respStmt>
			<orgName>University of Ottawa</orgName>
		</respStmt>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<monogr>
		<title level="m" type="main">Cochrane Effective Practice Organisation of Care. EPOC Resources for review authors</title>
		<ptr target="epoc.cochrane.org/resources/epoc-resources-review-authors" />
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<monogr>
		<title level="m" type="main">The GRADE Working Group. GRADE handbook for grading quality of evidence and strength of recommendations</title>
		<author>
			<persName><forename type="first">Hbj</forename><surname>Schünemann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Guyatt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oxman</surname></persName>
		</author>
		<ptr target="guidelinedevelopment.org/handbook" />
		<imprint>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">Pna</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Tambyah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Mo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yilmaz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA</title>
		<imprint>
			<biblScope unit="volume">320</biblScope>
			<biblScope unit="page" from="984" to="e94" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">PRO: carbapenems should be used for ALL infections caused by ceftriaxone-resistant Enterobacterales</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Isler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pna</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAC Antimicrob Resist</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">13</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">CON: carbapenems are NOT necessary for all infections caused by ceftriaxone-resistant Enterobacterales</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rodriguez-Bano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascual</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAC Antimicrob Resist</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">112</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Antecedent carbapenem exposure as a risk factor for non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae and carbapenemaseproducing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">K</forename><surname>Marimuthu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">T</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Bpz</forename><surname>Cherng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rkc</forename><surname>Fong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Pada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>De</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="845" to="e919" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Association between minimum inhibitory concentration, betalactamase genes and mortality for patients treated with piperacillin/ tazobactam or meropenem from the MERINO study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Chatfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Tambyah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>De</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
	<note>73:e3842e50</note>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections caused by AmpC beta-lactamase-producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp., or Serratia marcescens: a pilot multicenter randomized controlled trial (ME-RINO-2)</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Lye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Schneider</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">387</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">A multinational, preregistered cohort study of betalactam/beta-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Perez-Galera</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salamanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Cueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Calbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Almirante</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="4159" to="4e69" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Comparable outcomes for beta-lactam/beta-lactamase inhibitor combinations and carbapenems in definitive treatment of bloodstream infections caused by cefotaxime-resistant Escherichia coli or Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Jureen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chew</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Ali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Paynter</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infect Control</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Empiric piperacillin-tazobactam versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Ng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">X</forename><surname>Khong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">P</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chow</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Tambyah</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">153696</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum beta-lactamase bacteremia</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Rock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Lautenbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1319" to="e1325" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Carbapenems and piperacillin/tazobactam for the treatment of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">Y</forename><surname>Chu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">80</biblScope>
			<biblScope unit="page" from="222" to="e226" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Piperacillintazobactam versus other antibacterial agents for treatment of bloodstream infections due to AmpC beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">L</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Seval</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Giddins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="e00276" to="e317" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Treatment efficacy and superinfection rates in complicated urinarytract infections treated with ertapenem or piperacillin tazobactam</title>
		<author>
			<persName><forename type="first">M</forename><surname>Dizbay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Ozger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Karasahin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">F</forename><surname>Karasahin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Turk J Med Sci</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1760" to="e1764" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Efficacy of beta-lactam/beta-lactamase inhibitor combinations for the treatment of bloodstream infection due to extended-spectrum-betalactamase-producing Enterobacteriaceae in hematological patients with neutropenia</title>
		<author>
			<persName><forename type="first">C</forename><surname>Gudiol</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Royo-Cebrecos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Abdala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Akova</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Maestro-De</forename><surname>La Calle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
	<note>61:e00164e217</note>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Bacteremia due to extended-spectrum-beta-lactamase-producing Enterobacter cloacae: role of carbapenem therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="3551" to="e3556" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria G. beta-Lactam/betalactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rodriguez-Bano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Navarro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Retamar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Picon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Pascual</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="167" to="e74" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamaseproducing Escherichia coli</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">B</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">404</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Role of piperacillin/tazobactam as a carbapenem-sparing antibiotic for treatment of acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Yoon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Sohn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="410" to="e415" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy</title>
		<author>
			<persName><forename type="first">N</forename><surname>Nasir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ahmed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Razi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Awan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Mahmood</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Res Notes</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">611</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Is piperacillin-tazobactam effective for the treatment of pyelonephritis caused by extended-spectrum beta-lactamase-producing organisms?</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Sharara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Amoah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">D</forename><surname>Pana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Simner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Cosgrove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="331" to="e337" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Risk factors and outcomes in non-transplant patients with extended-spectrum beta-lactamase-producing Escherichia coli bacteremia: a retrospective study from 2013 to</title>
		<author>
			<persName><forename type="first">T</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ji</forename><forename type="middle">J</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infect Control</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">144</biblScope>
			<date type="published" when="2016">2016. 2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Appropriate noncarbapenems are not inferior to carbapenems as initial empirical therapy for bacteremia caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae: a propensity score weighted multicenter cohort study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Joo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">K</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Park</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="305" to="e311" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Clinical outcomes of elderly patients with bloodstream infections due to extendedspectrum beta-lactamase-producing Enterobacteriaceae in an Italian Internal Medicine ward</title>
		<author>
			<persName><forename type="first">S</forename><surname>Meini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Laureano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tascini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Arena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Fani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Frullini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Intern Med</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="50" to="e56" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Mortality caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae bacteremia; a case control study: alert to Enterobacteriaceae strains with high minimum inhibitory concentrations of piperacillin/tazobactam</title>
		<author>
			<persName><forename type="first">H</forename><surname>Namikawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yamairi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Shibata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Fujimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Takizawa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">94</biblScope>
			<biblScope unit="page" from="287" to="e92" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Association of high mortality with extended-spectrum beta-lactamase (ESBL) positive cultures in community acquired infections</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ray</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Anand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Purwar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Samanta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">V</forename><surname>Upadhye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gupta</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Crit Care</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="page" from="255" to="e60" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Carbapenems versus piperacillin-tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamaseproducing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">H</forename><surname>Ofer-Friedman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Shefler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tirosh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tal-Jasper</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Kandipalli</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="981" to="e985" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Clinical outcome of empiric antimicrobial therapy of bacteremia due to extendedspectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">P</forename><surname>Chaubey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Pitout</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dalton</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Ross</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Church</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>Gregson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Res Notes</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">116</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli</title>
		<author>
			<persName><forename type="first">T</forename><surname>Chopra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Veltman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tansek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="3936" to="e3942" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">M</forename><surname>Falcone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Vena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Mezzatesta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Caio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Goldoni</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Ig</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="293" to="e304" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Leu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Microbiol Immunol Infect</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="496" to="e502" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Clinical outcome of extendedspectrum beta-lactamase-producing Escherichia coli bacteremia in an area with high endemicity</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">K</forename><surname>To</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">U</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Tse</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">C</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>e120e4</note>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum betalactamase (ESBL) or AmpC beta-lactamase: a propensity score study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Meije</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Pigrau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fernandez-Hidalgo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Clemente</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sanz</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">54</biblScope>
			<biblScope unit="page" from="189" to="e96" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Empiric therapy with carbapenem-sparing regimens for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: results from the INCREMENT Cohort</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">R</forename><surname>Palacios-Baena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Calbo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Almirante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oliver</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="1615" to="e1623" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Gottberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mohapatra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Casellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goossens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="31" to="e37" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">L</forename><surname>Collins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moshos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bheemreddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Sunkara</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="2173" to="e2177" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Ertapenem in the treatment of bacteremia caused by extended-spectrum beta-lactamaseproducing Escherichia coli: a propensity score analysis</title>
		<author>
			<persName><forename type="first">U</forename><forename type="middle">I</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">C</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="47" to="e52" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational preregistered cohort study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Almirante</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Martinez-Martinez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="1672" to="1e80" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Carbapenem therapy for bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Tsui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="150" to="e153" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-beta-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial</title>
		<author>
			<persName><forename type="first">P</forename><surname>Rattanaumpawan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Werarak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Jitmuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kiratisin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Thamlikitkul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">183</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Treatment of ESBL-producing Klebsiella pneumoniae bacteraemia with carbapenems or flomoxef: a retrospective study and laboratory analysis of the isolates</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Liu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1074" to="e1077" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Discrepancy between effects of carbapenems and flomoxef in treating nosocomial hemodialysis access-related bacteremia secondary to extended spectrum betalactamase producing Klebsiella pneumoniae in patients on maintenance hemodialysis</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">R</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">206</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Comparative effectiveness of flomoxef versus carbapenems in the treatment of bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae with emphasis on minimum inhibitory concentration of flomoxef: a retrospective study</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chien</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="610" to="e615" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsumura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yamamoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Nagao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Komori</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Fujita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hayashi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="5107" to="e5113" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Cefmetazole for bacteremia caused by ESBL-producing Enterobacteriaceae comparing with carbapenems</title>
		<author>
			<persName><forename type="first">T</forename><surname>Fukuchi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kobayashi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Nakamura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ohji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">427</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">C</forename><surname>Tsui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Ko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="488" to="e95" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Girdwood</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Gopaul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Tekle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Roberts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">D</forename><surname>Harris</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="781" to="e788" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC betalactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Blanchette</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Kuti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Nicolau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Nailor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="803" to="e808" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcomes in patients infected by cefepime-susceptible dose-dependent isolates</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="7558" to="7e63" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Siedner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">B</forename><surname>Guzman-Suarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Kubiak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Baghdady</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Ferraro</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="1554" to="1e63" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Cefepime therapy for cefepime-susceptible extended-spectrum betalactamase-producing Enterobacteriaceae bacteremia</title>
		<author>
			<persName><forename type="first">R</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Cosgrove</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tschudin-Sutter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Turnbull</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Hsu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">132</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended-spectrum beta-lactamase: treatment outcome of patients receiving imipenem or ciprofloxacin</title>
		<author>
			<persName><forename type="first">A</forename><surname>Endimiani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Luzzaro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lombardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Coli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Tamborini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="243" to="e51" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Fluoroquinolone therapy for bloodstream infections caused by extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Lo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Microbiol Immunol Infect</title>
		<imprint>
			<biblScope unit="volume">50</biblScope>
			<biblScope unit="page" from="355" to="e61" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs b-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Punjabi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Deresinski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Holubar</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">364</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Aminoglycoside versus carbapenem or piperacillin/tazobactam treatment for bloodstream infections of urinary source caused by Gram-negative ESBL-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">I</forename><surname>Zohar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Yossepowitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ssb</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Maor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">75</biblScope>
			<biblScope unit="page" from="458" to="e65" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Outcomes and risk factors for mortality in community-onset bacteremia caused by extendedspectrum beta-lactamase-producing Escherichia coli, with a special emphasis on antimicrobial therapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">I</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Wi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Peck</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">Y</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="519" to="e525" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2/3 randomized trial</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Rice</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Dane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Stus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Sagan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Fedosiuk</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="2045" to="2e56" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<monogr>
		<title level="m" type="main">Fosfomycin vs meropenem or ceftriaxone for bacteraemic urinary tract infections caused by multidrug-resistant Escherichia coli: a randomised trial (FOREST) 30th European Congress of Clinical Microbiology &amp; Infectious Diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Sojo-Dorado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Opez-Hern Andez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Borreguero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
		<imprint>
			<date type="published" when="2020">2020</date>
			<publisher>European Society of Infectious Diseases</publisher>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extendedspectrum beta-lactamase urinary tract infections</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Veve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Wagner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Kenney</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Grunwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="56" to="e60" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">Once-daily plazomicin for complicated urinary tract infections</title>
		<author>
			<persName><forename type="first">Fme</forename><surname>Wagenlehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">J</forename><surname>Cloutier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Komirenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Cebrik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">R</forename><surname>Keepers</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="729" to="e740" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Does once-daily dosing prevent nephrotoxicity in all aminoglycosides equally?</title>
		<author>
			<persName><forename type="first">G</forename><surname>Beaucaire</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page" from="355" to="e60" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">A</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Shimada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Harada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Iwata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kamiya</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="159" to="e63" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">Alternatives to carbapenems for infections caused by ESBL-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">B</forename><surname>Pilmis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Parize</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Zahar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Lortholary</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1263" to="e1265" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Senard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lafaurie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lesprit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lescure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Therby</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="121" to="e129" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum betalactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Altshuler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Paris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fedorenko</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page" from="155" to="e158" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched caseecontrol study</title>
		<author>
			<persName><forename type="first">T</forename><surname>Delory</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Gravier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Pluart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Gaube</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Simeon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Davido</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page">106361</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Outcome of antimicrobial therapy of pediatric urinary tract infections caused by extendedspectrum beta-lactamase-producing Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">B</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">R</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">G</forename><surname>Kang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">S</forename><surname>Ha</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Chemother</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="415" to="e421" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">The efficacy of noncarbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum beta-lactamase-producing Escherichia coli</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">K</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">G</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">Y</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="2848" to="2e56" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Efficacy and safety of ceftazidime-avibactam versus imipenemcilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">D</forename><surname>Gonzalez Patzan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Stricklin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Duttaroy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Kreidly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lipka</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Curr Med Res Opin</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="1921" to="e1931" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">Ceftazidime-avibactam or best available therapy in patients with ceftazidimeresistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Laud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Newell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wardman</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="661" to="e73" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Wagenlehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Sobel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Newell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Stone</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="754" to="e62" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">M</forename><surname>Wagenlehner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Umeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Steenbergen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Yuan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">O</forename><surname>Darouiche</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">The Lancet</title>
		<imprint>
			<biblScope unit="volume">385</biblScope>
			<biblScope unit="page" from="1949" to="1e56" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Melnyk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Datsenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Dzyublik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Glumcher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="140" to="e51" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study</title>
		<author>
			<persName><forename type="first">G</forename><surname>Zanetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bally</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Greub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garbino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kinge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Lew</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="3442" to="e3447" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Ceftazidimeavibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial</title>
		<author>
			<persName><forename type="first">A</forename><surname>Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Zhong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Pachl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">F</forename><surname>Timsit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kollef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="285" to="e95" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Kollef</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Novacek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Kivistik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rea-Neto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Shime</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Martin-Loeches</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="1299" to="e311" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">High-dose cefepime as an alternative treatment for infections caused by TEM-24 ESBL-producing Enterobacter aerogenes in severely-ill patients</title>
		<author>
			<persName><forename type="first">K</forename><surname>Goethaert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Van Looveren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Lammens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Jansens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Baraniak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gniadkowski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="56" to="e62" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<monogr>
		<title level="m" type="main">FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning</title>
		<author>
			<persName><surname>Fda</surname></persName>
		</author>
		<ptr target="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-increased-risk-death-iv-antibacterial-tygacil-tigecycline" />
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">E</forename><surname>Mazuski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Gasink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Armstrong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Broadhurst</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">G</forename><surname>Stone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Rank</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1380" to="e1389" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Ceftolozane/tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hershberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Popejoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Friedland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Steenbergen</surname></persName>
		</author>
		<ptr target="http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/510/CN-01088510/frame.html" />
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
	<note>Internet</note>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intraabdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial</title>
		<author>
			<persName><forename type="first">J</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Evans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Slepavicius</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Marsh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Tsai</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">JAMA Surg</title>
		<imprint>
			<biblScope unit="volume">152</biblScope>
			<biblScope unit="page" from="224" to="e232" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenemresistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Duin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Lok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Earley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Perez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">66</biblScope>
			<biblScope unit="page" from="163" to="e71" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Potoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">V</forename><surname>Marini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="883" to="e917" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Caston</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lacort-Peralta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martin</forename><forename type="middle">-</forename><surname>Davila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Loeches</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Tabares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Temkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="118" to="e123" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Trecarichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Corona</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mussini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="355" to="e64" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Efficacy of ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Alraddadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Saeedi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Qutub</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alshukairi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Hassanien</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wali</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page">772</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Potoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Haidar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="1615" to="e1618" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">Emergence of ceftazidime/avibactam non-susceptibility in an MDR Klebsiella pneumoniae isolate</title>
		<author>
			<persName><forename type="first">A</forename><surname>Both</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Buttner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perbandt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Belmar</forename><surname>Campos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Christner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="2483" to="e2488" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">M</forename><surname>Humphries</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Hemarajata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">W</forename><surname>Ward</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Hindler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Miller</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="6605" to="e6607" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment</title>
		<author>
			<persName><forename type="first">K</forename><surname>Raisanen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Koivula</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Ilmavirta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Puranen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Kallonen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Lyytikainen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">1900256</biblScope>
			<date type="published" when="2018">2018. 2019</date>
			<pubPlace>Finland</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">Emergence of ceftazidime/ avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Hong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Du</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="124" to="e125" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">In vitro selection of ceftazidime-avibactam resistance in Enterobacteriaceae with KPC-3 carbapenemase</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Livermore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Jamrozy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mushtaq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Nichols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mustafa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="5324" to="e5330" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">Emergence of ceftazidime-avibactam resistance due to plasmid-borne bla(KPC-3) mutations during treatment of carbapenem-resistant Klebsiella pneumoniae infections</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Chavda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Snyder</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="2097" to="0e116" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae infections: a retrospective observational multicenter study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Raffaelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mantengoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mularoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Venditti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1664" to="1e76" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB beta-lactamase variant with a Lys234Arg substitution</title>
		<author>
			<persName><forename type="first">E</forename><surname>Voulgari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">D</forename><surname>Kotsakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Giannopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Perivolioti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Tzouvelekis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Miriagou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<date type="published" when="2019">2019. 2020. 1900766</date>
			<pubPlace>Greece</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidimeavibactam resistance mediated through a VEB-1-mutant (VEB-25</title>
		<author>
			<persName><forename type="first">I</forename><surname>Galani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Karaiskos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Souli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Papoutsaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Galani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gkoufa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Euro Surveill</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<date type="published" when="2019-10">September to October 2019. 2020. 2000028</date>
			<pubPlace>Greece</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Overview of meropenemvaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Petty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Henig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Drug Resist</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1461" to="1e72" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Effect and safety of meropenem-vaborbactam versus bestavailable therapy in patients with carbapenem-resistant Enterobacteriaceae infections: the TANGO II Randomized Clinical Trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Wunderink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Giamarellos-Bourboulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Rahav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Vazquez</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Dis Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="439" to="e55" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Livermore</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Warner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mushtaq</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="2286" to="2e90" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">Phase 2, Dose-ranging study of relebactam with imipenem-cilastatin in subjects with complicated intra-abdominal infection</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lucasti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Vasile</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Sandesc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Venskutonis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mcleroth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Lala</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="6234" to="e6243" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections</title>
		<author>
			<persName><forename type="first">M</forename><surname>Sims</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Mariyanovski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Mcleroth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Akers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Brown</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="2616" to="e2626" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">A randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/ tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study)</title>
		<author>
			<persName><forename type="first">I</forename><surname>Titov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Wunderink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Roquilly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rodriguez</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>David-Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="4539" to="e4548" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<monogr>
		<title level="m" type="main">Imipenem/cilastatin (IMI)/relebactam (REL) for treatment of Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP) caused by imipenem-nonsusceptible pathogens: subgroup analysis of the RESTORE-IMI 2 trial. 31st European congress of clinical microbiology &amp; infectious diseases</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">W</forename><surname>Hilbert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Losada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Deryke</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Du</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2021">2021</date>
			<publisher>European Society of Infectious Diseases</publisher>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">RESTORE-IMI 1: a multicenter, randomized, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections</title>
		<author>
			<persName><forename type="first">J</forename><surname>Motsch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Murta</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Stus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Koksal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Lyulko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Boucher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">W</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1799" to="e808" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial</title>
		<author>
			<persName><forename type="first">S</forename><surname>Portsmouth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Veenhuyzen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Echols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Machida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jca</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ariyasu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1319" to="e1328" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Wunderink</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsunaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ariyasu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Clevenbergh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Echols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="213" to="e225" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Echols</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Matsunaga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ariyasu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Doi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ferrer</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="226" to="e240" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">A minimalistic approach to identify substrate binding features in B1 Metallobeta-lactamases</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Poeylaut-Palena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">E</forename><surname>Tomatis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Karsisiotis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Damblon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Mata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Vila</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Bioorg Med Chem Lett</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="5171" to="e5174" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae</title>
		<author>
			<persName><forename type="first">M</forename><surname>Falcone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Russo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Iacovelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Restuccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Ceccarelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giordano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="444" to="e50" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Hospital readmissions in patients with carbapenem-resistant Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Messina</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Salata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Kalayjian</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Control Hosp Epidemiol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="281" to="e288" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Impact of therapy and strain type on outcomes in urinary tract infections caused by carbapenem-resistant Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">D</forename><surname>Van Duin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Kalayjian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Salata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="1203" to="e1211" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b124">
	<analytic>
		<title level="a" type="main">Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Satlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Kubin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Blumenthal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">B</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Furuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Wilson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">55</biblScope>
			<biblScope unit="page" from="5893" to="e5899" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b125">
	<analytic>
		<title level="a" type="main">Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">M</forename><surname>Gonzalez-Padilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Torre</forename><forename type="middle">-</forename><surname>Cisneros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Rivera-Espinar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Pontes-Moreno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Cerero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pascual</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="905" to="e913" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b126">
	<analytic>
		<title level="a" type="main">The role of therapy with aminoglycoside in the outcomes of kidney transplant recipients infected with polymyxin-and carbapenemresistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oliveira</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Cury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Francisco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dos</forename><surname>Santos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">F</forename><surname>Spadao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="755" to="e65" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b127">
	<analytic>
		<title level="a" type="main">Early use of polymyxin B reduces the mortality of carbapenem-resistant Klebsiella pneumoniae bloodstream infection</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Braz J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="60" to="e65" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b128">
	<analytic>
		<title level="a" type="main">Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes</title>
		<author>
			<persName><forename type="first">M</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">A</forename><surname>Eschenauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bryan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Neil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Furuya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">Y</forename><surname>Della-Latta</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="180" to="e184" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b129">
	<analytic>
		<title level="a" type="main">Cefepime combined with amoxicillin/ clavulanic acid: a new choice for the KPC-producing K. pneumoniae infection</title>
		<author>
			<persName><forename type="first">S</forename><surname>Ji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Mu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="page" from="108" to="e114" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b130">
	<analytic>
		<title level="a" type="main">Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections</title>
		<author>
			<persName><forename type="first">K</forename><surname>Ku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Moshos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bheemreddy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bhargava</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="983" to="e987" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b131">
	<analytic>
		<title level="a" type="main">Infections due to carbapenem resistant Enterobacteriaceae among Saudi Arabian hospitalized patients: a matched caseecontrol study</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Garbati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sakkijha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abushaheen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">3961684</biblScope>
			<date type="published" when="2016">2016. 2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b132">
	<analytic>
		<title level="a" type="main">High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria</title>
		<author>
			<persName><forename type="first">De</forename><surname>Pascale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Montini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Pennisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bernini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Maviglia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Bello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page">90</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b133">
	<analytic>
		<title level="a" type="main">High-dose tigecycline for the treatment of nosocomial carbapenem-resistant Klebsiella pneumoniae bloodstream infections: a retrospective cohort study</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">T</forename><surname>Geng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine (Balt)</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="page">9961</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b134">
	<analytic>
		<title level="a" type="main">Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation</title>
		<author>
			<persName><forename type="first">A</forename><surname>Michalopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Virtzili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Rafailidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chalevelakis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Damala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Falagas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="184" to="e186" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b135">
	<analytic>
		<title level="a" type="main">Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drugresistant carbapenemase-producing Gram-negative bacteria</title>
		<author>
			<persName><forename type="first">K</forename><surname>Pontikis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Karaiskos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bastani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Dimopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kalogirou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Katsiari</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="52" to="e59" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b136">
	<analytic>
		<title level="a" type="main">Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Karageorgopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Miriagou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Tzouvelekis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Spyridopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">67</biblScope>
			<biblScope unit="page" from="2777" to="e2779" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b137">
	<analytic>
		<title level="a" type="main">Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenemresistant Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">F</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Che</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Zhang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Exp Ther Med</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="1003" to="e1010" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b138">
	<analytic>
		<title level="a" type="main">The role of trimethoprim/sulfamethoxazole in the treatment of infections caused by carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Luterbach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Boshe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">I</forename><surname>Henderson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Cober</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Salata</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">351</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b139">
	<analytic>
		<title level="a" type="main">IGNITE4: results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gardovskis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Montravers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Sway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Evans</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="921" to="e929" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b140">
	<analytic>
		<title level="a" type="main">Plazomicin for infections caused by carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Mckinnell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Dwyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Talbot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Connolly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Friedland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Smith</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">380</biblScope>
			<biblScope unit="page" from="791" to="e793" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b141">
	<analytic>
		<title level="a" type="main">Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Bergamasco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Barroso</forename><surname>Barbosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oliveira</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Cipullo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Moreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Baia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Transpl Infect Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<date type="published" when="2012">2012. 198e205</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b142">
	<analytic>
		<title level="a" type="main">High rate of colistin resistance among patients with carbapenemresistant Klebsiella pneumoniae infection accounts for an excess of mortality</title>
		<author>
			<persName><forename type="first">A</forename><surname>Capone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Fortini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Meledandri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ballardini</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
	<note>E23e30</note>
</biblStruct>

<biblStruct xml:id="b143">
	<analytic>
		<title level="a" type="main">Clinical features of patients with carbapenem nonsusceptible Klebsiella pneumoniae and Escherichia coli in intensive care units: a nationwide multicenter study in Taiwan</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">K</forename><surname>Siu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Microbiol Immunol Infect</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="219" to="e225" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b144">
	<analytic>
		<title level="a" type="main">Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy</title>
		<author>
			<persName><forename type="first">R</forename><surname>Crusio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Changawala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Tiu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Van Ginkel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Scand J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1" to="e8" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b145">
	<analytic>
		<title level="a" type="main">Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tsaousi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">S</forename><surname>Tzouvelekis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Anyfantis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Psichogiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Argyropoulou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="2322" to="e2328" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b146">
	<analytic>
		<title level="a" type="main">A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>De Maio Carrilho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gaudereto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Perozin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Urbano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Camargo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">629</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b147">
	<analytic>
		<title level="a" type="main">Clinical characteristics of carbapenem-resistant Klebsiella pneumoniae infections in ill and colonized children in Colombia</title>
		<author>
			<persName><forename type="first">A</forename><surname>Diaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">C</forename><surname>Ortiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Trujillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Garces</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Jaimes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">V</forename><surname>Restrepo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pediatr Infect Dis J</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="237" to="e241" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b148">
	<analytic>
		<title level="a" type="main">Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae in cancer patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Pierrotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Filho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Ibrahim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Magri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Bonazzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="277" to="e86" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b149">
	<analytic>
		<title level="a" type="main">Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gomez-Simmonds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Eiras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Loo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Jenkins</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Whittier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="3601" to="e3607" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b150">
	<analytic>
		<title level="a" type="main">Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study</title>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Salamanca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>De Cueto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Viale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Pano-Pardo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="726" to="e734" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b151">
	<analytic>
		<title level="a" type="main">Carbapenem-resistant Klebsiella pneumoniae infections in a Greek intensive care unit: molecular characterisation and treatment challenges</title>
		<author>
			<persName><forename type="first">M</forename><surname>Katsiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Panagiota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Likousi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Roussou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Polemis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Alkiviadis</forename><surname>Vatopoulos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Glob Antimicrob Resist</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="123" to="e127" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b152">
	<analytic>
		<title level="a" type="main">Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections</title>
		<author>
			<persName><forename type="first">M</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heil</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kuriakose</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Bias</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>El-Beyrouty</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="449" to="e517" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b153">
	<analytic>
		<title level="a" type="main">Infections caused by carbapenem-resistant Klebsiella pneumoniae among patients in intensive care units in Greece: a multi-centre study on clinical outcome and therapeutic options</title>
		<author>
			<persName><forename type="first">F</forename><surname>Kontopidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Giamarellou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Katerelos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Maragos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Kioumis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Trikka-Graphakos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page" from="117" to="e123" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b154">
	<analytic>
		<title level="a" type="main">Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: importance of combination therapy without colistin and carbapenems</title>
		<author>
			<persName><forename type="first">I</forename><surname>Machuca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Gutierrez-Gutierrez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gracia-Ahufinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rivera</forename><surname>Espinar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Cano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Guzman-Puche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="406" to="e417" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b155">
	<analytic>
		<title level="a" type="main">Invasive carbapenemresistant Enterobacteriaceae infection at a paediatric hospital: a case series</title>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">O</forename><surname>Malande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Du</forename><surname>Plessis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rip</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bamford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Eley</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">S Afr Med J</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="877" to="e82" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b156">
	<analytic>
		<title level="a" type="main">Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rods</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Nelson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">P</forename><surname>Eiras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gomez-Simmonds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Loo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Satlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">G</forename><surname>Jenkins</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="7000" to="e7006" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b157">
	<analytic>
		<title level="a" type="main">Carbapenemase-producing Klebsiella pneumoniae bloodstream infection in critically ill patients: risk factors and predictors of mortality</title>
		<author>
			<persName><forename type="first">M</forename><surname>Papadimitriou-Olivgeris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fligou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bartzavali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zotou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Spyropoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Koutsileou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1125" to="e1131" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b158">
	<analytic>
		<title level="a" type="main">Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial</title>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Durante</forename><forename type="middle">-</forename><surname>Mangoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Yahav</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Carmeli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Benattar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Infect Dis</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="391" to="e400" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b159">
	<analytic>
		<title level="a" type="main">Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens</title>
		<author>
			<persName><forename type="first">Z</forename><forename type="middle">A</forename><surname>Qureshi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename><surname>Potoski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Kilayko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Sandovsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Sordillo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="2108" to="e2113" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b160">
	<analytic>
		<title level="a" type="main">Aminoglycosides for treatment of bacteremia due to carbapenem-resistant Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="3187" to="3e92" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b161">
	<analytic>
		<title level="a" type="main">Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases</title>
		<author>
			<persName><forename type="first">P</forename><surname>Tofas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Skiada</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Angelopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Sipsas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Pavlopoulou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tsaousi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="335" to="e339" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b162">
	<analytic>
		<title level="a" type="main">Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Trecarichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giacobbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="page" from="2133" to="e2143" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b163">
	<analytic>
		<title level="a" type="main">Risk factors for mortality in patients with ventilator-associated pneumonia caused by carbapenem-resistant Enterobacteriaceae</title>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">F</forename><surname>Tuon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Graf</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Merlini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rocha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Stallbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">N</forename><surname>Arend</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Braz J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="1" to="e6" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b164">
	<analytic>
		<title level="a" type="main">Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American countries</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">V</forename><surname>Villegas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Pallares</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Escandon-</forename><surname>Vargas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hernandez-Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Correa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Alvarez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">154092</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b165">
	<analytic>
		<title level="a" type="main">Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zarkotou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Pournaras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tselioti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Dragoumanos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pitiriga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ranellou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="1798" to="e803" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b166">
	<analytic>
		<title level="a" type="main">Combination therapy with polymyxin B for carbapenemase-producing Klebsiella pneumoniae bloodstream infection</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename><surname>Medeiros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Rigatto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Falci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Zavascki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="152" to="e157" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b167">
	<analytic>
		<title level="a" type="main">Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">J</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="651" to="e659" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b168">
	<analytic>
		<title level="a" type="main">Appropriate treatment for bloodstream infections due to carbapenem-resistant Klebsiella pneumoniae and Escherichia coli: a nationwide multicenter study in Taiwan</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Forum Infect Dis</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">336</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b169">
	<analytic>
		<title level="a" type="main">Colonization and infection due to carbapenemase-producing Enterobacteriaceae in liver and lung transplant recipients and donor-derived transmission: a prospective cohort study conducted in Italy</title>
		<author>
			<persName><forename type="first">G</forename><surname>Errico</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gagliotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Monaco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Masiero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gaibani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ambretti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="203" to="e209" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b170">
	<analytic>
		<title level="a" type="main">Polymyxin monotherapy or in combination against carbapenem-resistant bacteria: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">O</forename><surname>Zusman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Altunin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Koppel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Dishon</forename><surname>Benattar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Gedik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="29" to="e39" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b171">
	<analytic>
		<title level="a" type="main">Monotherapy versus combination therapy for multidrug-resistant Gramnegative infections: systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">A</forename><surname>Schmid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Wolfensberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Nemeth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">W</forename><surname>Schreiber</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sax</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">P</forename><surname>Kuster</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">15290</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b172">
	<analytic>
		<title level="a" type="main">The efficacy and safety of tigecycline for the treatment of bloodstream infections: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Pan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Clin Microbiol Antimicrob</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b173">
	<analytic>
		<title level="a" type="main">Pharmacokinetic and pharmacodynamic evaluation of tigecycline</title>
		<author>
			<persName><forename type="first">H</forename><surname>Giamarellou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Poulakou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Expert Opin Drug Metab Toxicol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1459" to="1e70" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b174">
	<analytic>
		<title level="a" type="main">International consensus guidelines for the optimal use of the polymyxins: endorsed by the American college of clinical pharmacy (ACCP)</title>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Tsuji</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Zavascki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Paul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Forrest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="m">European society of clinical microbiology and infectious diseases (ESCMID), infectious diseases society of America (IDSA), international society for antiinfective pharmacology (ISAP), society of critical care medicine (SCCM), and society of infectious diseases pharmacists (SIDP)</title>
		<imprint>
			<date type="published" when="2019">2019</date>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="10" to="e39" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b175">
	<analytic>
		<title level="a" type="main">Treatment of KPC-producing Enterobacteriaceae: suboptimal efficacy of polymyxins</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>De Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">B</forename><surname>De Assis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Boas</forename><surname>Do Prado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Machado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Abdala</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microb Infect</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page" from="179" to="e180" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b176">
	<analytic>
		<title level="a" type="main">Excess mortality associated with colistin-tigecycline compared with colistincarbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study</title>
		<author>
			<persName><forename type="first">A</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Liao</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="1194" to="e204" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b177">
	<monogr>
		<title level="m" type="main">Results from the OVERCOME Trial: colistin monotherapy versus combination therapy for the treatment of pneumonia or bloodstream infection due to extensively drug resistant Gram-negative bacilli. 31st European congress of clinical microbiology &amp; infectious diseases</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Thamlikitkul</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2021">2021. 2021</date>
			<publisher>European Society of Infectious Disease</publisher>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b178">
	<analytic>
		<title level="a" type="main">Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection</title>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Trecarichi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">R</forename><surname>Giacobbe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Rosa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Bassetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Bartoloni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">51</biblScope>
			<biblScope unit="page">2448</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b179">
	<analytic>
		<title level="a" type="main">In vitro evaluation of double carbapenem and colistin combinations against OXA-48, NDM carbapenemaseproducing colistin-resistant Klebsiella pneumoniae strains</title>
		<author>
			<persName><forename type="first">F</forename><surname>Erdem</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abulaila</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Aktas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Oncul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infect Control</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">70</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b180">
	<analytic>
		<title level="a" type="main">Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae</title>
		<author>
			<persName><forename type="first">A</forename><surname>Oliva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Gizzi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Mascellino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Cipolla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>'abramo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">D'</forename><surname>Agostino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="147" to="e53" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b181">
	<analytic>
		<title level="a" type="main">Role of double-carbapenem regimen in the treatment of infections due to carbapenemase producing carbapenem-resistant Enterobacteriaceae: a single-center, observational study</title>
		<author>
			<persName><forename type="first">F</forename><surname>Cancelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Oliva</surname></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Angelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mascellino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Mastroianni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Vullo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biomed Res Int</title>
		<imprint>
			<biblScope unit="page">2785696</biblScope>
			<date type="published" when="2018">2018. 2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b182">
	<analytic>
		<title level="a" type="main">Double carbapenem as a rescue strategy for the treatment of severe carbapenemase-producing Klebsiella pneumoniae infections: a two-center, matched caseecontrol study</title>
		<author>
			<persName><forename type="first">De</forename><surname>Pascale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Martucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Montini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Panarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Cutuli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Di</forename><surname>Carlo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Crit Care</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">173</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b183">
	<analytic>
		<title level="a" type="main">Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): from test tube to clinical practice</title>
		<author>
			<persName><forename type="first">V</forename><surname>Venugopalan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Nogid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">N</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Rahman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">E</forename><surname>Bias</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infect Dis (Lond)</title>
		<imprint>
			<biblScope unit="volume">49</biblScope>
			<biblScope unit="page" from="867" to="e70" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b184">
	<analytic>
		<title level="a" type="main">Pneumonia and renal replacement therapy are risk factors for ceftazidimeavibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">G</forename><surname>Press</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">N</forename><surname>Kreiswirth</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b185">
	<analytic>
		<title level="a" type="main">Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam</title>
		<author>
			<persName><forename type="first">C</forename><surname>De La Calle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Rodriguez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Morata</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Marco</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Cardozo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garcia</forename><forename type="middle">-</forename><surname>Vidal</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="520" to="e524" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b186">
	<analytic>
		<title level="a" type="main">Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study</title>
		<author>
			<persName><forename type="first">M</forename><surname>Tumbarello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Raffaelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mantengoli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mularoni</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Venditti</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1664" to="1e76" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b187">
	<analytic>
		<title level="a" type="main">In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Karlowsky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Kazmierczak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Blm</forename><surname>De Jonge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Hackel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">F</forename><surname>Sahm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Bradford</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<date type="published" when="2015">2015. 2017</date>
		</imprint>
	</monogr>
	<note>61: e00472e517</note>
</biblStruct>

<biblStruct xml:id="b188">
	<analytic>
		<title level="a" type="main">Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Sader</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Mendes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename><surname>Pfaller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Shortridge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Flamm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Castanheira</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="1" to="e11" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b189">
	<analytic>
		<title level="a" type="main">Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection</title>
		<author>
			<persName><forename type="first">E</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rombauts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Tubau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Padulles</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Camara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Lozano</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">73</biblScope>
			<biblScope unit="page" from="1104" to="e1106" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b190">
	<analytic>
		<title level="a" type="main">Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing Enterobacterales</title>
		<author>
			<persName><forename type="first">M</forename><surname>Falcone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">L</forename><surname>Daikos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Tiseo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Bassoulis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Galfo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="1871" to="e1878" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b191">
	<analytic>
		<title level="a" type="main">Emergence of ceftazidime/avibactam resistance in KPC-3-producing Klebsiella pneumoniae in vivo</title>
		<author>
			<persName><forename type="first">S</forename><surname>Gottig</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Frank</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mungo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Nolte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Hogardt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Besier</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">74</biblScope>
			<biblScope unit="page" from="3211" to="e3216" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b192">
	<analytic>
		<title level="a" type="main">Ceftolozane/Tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Veve</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">S</forename><surname>Patel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">T</forename><surname>Gerlach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">71</biblScope>
			<biblScope unit="page" from="304" to="e310" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b193">
	<analytic>
		<title level="a" type="main">Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin</title>
		<author>
			<persName><forename type="first">A</forename><surname>Apisarnthanarak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mundy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">39</biblScope>
			<biblScope unit="page" from="271" to="e272" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b194">
	<analytic>
		<title level="a" type="main">Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">S</forename><surname>Akajagbor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Wilson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">D</forename><surname>Shere-Wolfe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Dakum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Charurat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">L</forename><surname>Gilliam</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="1300" to="e1303" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b195">
	<analytic>
		<title level="a" type="main">Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia</title>
		<author>
			<persName><forename type="first">T</forename><surname>Khawcharoenporn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Pruetpongpun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Tiamsak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Rutchanawech</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Mundy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Apisarnthanarak</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="378" to="e82" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b196">
	<analytic>
		<title level="a" type="main">Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin B in monotherapy in critically ill patients with Acinetobacter baumannii or Pseudomonas aeruginosa infections</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">H</forename><surname>Rigatto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">J</forename><surname>Vieira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Antochevis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">F</forename><surname>Behle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">T</forename><surname>Lopes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Zavascki</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="6575" to="6e80" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b197">
	<analytic>
		<title level="a" type="main">Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Falagas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">I</forename><surname>Rafailidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Ioannidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">G</forename><surname>Alexiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">K</forename><surname>Matthaiou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Karageorgopoulos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">35</biblScope>
			<biblScope unit="page" from="194" to="e199" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b198">
	<analytic>
		<title level="a" type="main">Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands</title>
		<author>
			<persName><forename type="first">M</forename><surname>Diaz-Canestro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Perianez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Mulet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Martin-Pena</forename><surname>Ml</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fraile</forename><forename type="middle">-</forename><surname>Ribot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Ayestaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="2191" to="e200" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b199">
	<analytic>
		<title level="a" type="main">Substantial targeting advantage achieved by pulmonary administration of colistin methanesulfonate in a large-animal model</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">B</forename><surname>Landersdorfer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">T</forename><surname>Lieu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Nguyen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Bischof</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">N</forename><surname>Meeusen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<date type="published" when="2017">2017. 01934e2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b200">
	<analytic>
		<title level="a" type="main">Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients</title>
		<author>
			<persName><forename type="first">M</forename><surname>Boisson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jacobs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Gregoire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Gobin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Marchand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Couet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="7331" to="e7339" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b201">
	<analytic>
		<title level="a" type="main">Efficacy and safety of high-dose ampicillin/sulbactam vs. colistin as monotherapy for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">P</forename><surname>Betrosian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Frantzeskaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Xanthaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">E</forename><surname>Douzinas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="432" to="e436" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b202">
	<analytic>
		<title level="a" type="main">Meropenem/colistin versus meropenem/ampicillinsulbactam in the treatment of carbapenem-resistant pneumonia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Khalili</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Shojaei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Mohammadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Beigmohammadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Abdollahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doomanlou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Comp Eff Res</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="901" to="e911" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b203">
	<analytic>
		<title level="a" type="main">Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Oliveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">V</forename><surname>Prado</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">F</forename><surname>Costa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Grinbaum</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">S</forename><surname>Levin</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">61</biblScope>
			<biblScope unit="page" from="1369" to="1e75" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b204">
	<analytic>
		<title level="a" type="main">Treatment of carbapenem-resistant Acinetobacter baumannii ventilatorassociated pneumonia: retrospective comparison between intravenous colistin and intravenous ampicillin-sulbactam</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zalts</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Neuberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hussein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Raz-Pasteur</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Geffen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Mashiach</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Ther</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="78" to="e85" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b205">
	<analytic>
		<title level="a" type="main">Interim study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter</title>
		<author>
			<persName><forename type="first">R</forename><surname>Mosaed</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Haghighi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kouchak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">M</forename><surname>Miri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Salarian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Shojaei</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Iran J Pharm Res</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="206" to="e213" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b206">
	<analytic>
		<title level="a" type="main">Effectiveness of tigecycline-based versus colistin-based therapy for treatment of pneumonia caused by multidrug-resistant Acinetobacter baumannii in a critical setting: a matched cohort analysis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Cheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">H</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page">102</biblScope>
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b207">
	<analytic>
		<title level="a" type="main">Comparable efficacy of tigecycline versus colistin therapy for multidrug-resistant and extensively drug-resistant Acinetobacter baumannii pneumonia in critically ill patients</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">Y</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Moon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Huh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Koh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">150642</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b208">
	<analytic>
		<title level="a" type="main">Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kwon</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Ahn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">Y</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">La</forename><surname>Ho</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Biol Pharm Bull</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="340" to="e346" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b209">
	<analytic>
		<title level="a" type="main">Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections</title>
		<author>
			<persName><forename type="first">De</forename><surname>Pascale</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Lisi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Ciotti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Gmp</forename><surname>Vallecoccia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Cutuli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Cascarano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intensive Care</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">94</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b210">
	<analytic>
		<title level="a" type="main">Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">T</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Tsao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Hsueh</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="1211" to="e1220" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b211">
	<analytic>
		<title level="a" type="main">Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrugresistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">F</forename><surname>Yeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">M</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Yang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page">374</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b212">
	<analytic>
		<title level="a" type="main">Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">A</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Sheu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="908" to="e909" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b213">
	<analytic>
		<title level="a" type="main">Comparison of tigecycline or cefoperazone/sulbactam therapy for bloodstream infection due to carbapenem-resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">T</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Yu</forename><forename type="middle">W</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Resist Infect Control</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">52</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b214">
	<analytic>
		<title level="a" type="main">Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: a retrospective study from a Chinese hospital</title>
		<author>
			<persName><forename type="first">H</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Fu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Medicine (Balt)</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="page">14937</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b215">
	<monogr>
		<title level="m" type="main">Cefiderocol advisory committee briefing document</title>
		<author>
			<persName><surname>Shionogi</surname></persName>
		</author>
		<imprint>
			<date type="published" when="2019">2019</date>
			<publisher>Shionogi</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b216">
	<analytic>
		<title level="a" type="main">Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Graves</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">H</forename><surname>Dellit</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Intensive Care Med</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="343" to="e348" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b217">
	<analytic>
		<title level="a" type="main">Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections</title>
		<author>
			<persName><forename type="first">R</forename><surname>Gounden</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Bamford</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Van Zyl-Smit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Cohen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Maartens</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">BMC Infect Dis</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">26</biblScope>
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b218">
	<analytic>
		<title level="a" type="main">Polymyxin B and doxycycline use in patients with multidrug-resistant Acinetobacter baumannii infections in the intensive care unit</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">P</forename><surname>Holloway</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Rouphael</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">M</forename><surname>Blumberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Pharmacother</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="1939" to="e1945" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b219">
	<analytic>
		<title level="a" type="main">Synergistic effect of colistin and rifampin against multidrug resistant Acinetobacter baumannii: a systematic review and meta-analysis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Mohammadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Khayat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Sayehmiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Soroush</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Sayehmiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Delfani</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Open Microbiol J</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="63" to="e71" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b220">
	<analytic>
		<title level="a" type="main">Activities of vancomycin-containing regimens against colistin-resistant Acinetobacter baumannii clinical strains</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>O'hara</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Ambe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">G</forename><surname>Casella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">M</forename><surname>Townsend</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">R</forename><surname>Pelletier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Ernst</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="2103" to="e2108" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b221">
	<analytic>
		<title level="a" type="main">Synergistic combinations of polymyxins</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">R</forename><surname>Lenhard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Nation</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">T</forename><surname>Tsuji</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">48</biblScope>
			<biblScope unit="page" from="607" to="e613" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b222">
	<analytic>
		<title level="a" type="main">An alternative strategy for combination therapy: interactions between polymyxin B and non-antibiotics</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">G</forename><surname>Otto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Van Gorp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Kloezen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meletiadis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Van Den Berg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Mouton</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="34" to="e39" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b223">
	<analytic>
		<title level="a" type="main">Clinical relevance of in vitro synergistic activity of antibiotics for multidrug-resistant Gramnegative infections: a systematic review</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Z</forename><surname>Vardakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Athanassaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Pitiriga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Falagas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Glob Antimicrob Resist</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="250" to="e259" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b224">
	<analytic>
		<title level="a" type="main">Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">G</forename><surname>Kalin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Alp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Akin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Coskun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Doganay</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Infection</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="37" to="e42" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b225">
	<analytic>
		<title level="a" type="main">Tigecycline in the treatment of infections from multi-drug resistant Gram-negative pathogens</title>
		<author>
			<persName><forename type="first">G</forename><surname>Poulakou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">V</forename><surname>Kontopidou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Paramythiotou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kompoti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Katsiari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Mainas</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="273" to="e84" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b226">
	<analytic>
		<title level="a" type="main">Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections</title>
		<author>
			<persName><forename type="first">R</forename><surname>Sirijatuphat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Thamlikitkul</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="5598" to="e601" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b227">
	<analytic>
		<title level="a" type="main">Multidrug and carbapenem-resistant Acinetobacter baumannii infections: factors associated with mortality</title>
		<author>
			<persName><forename type="first">A</forename><surname>Hernandez-Torres</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Garcia</forename><forename type="middle">-</forename><surname>Vazquez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Gomez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Canteras</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ruiz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yague</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Med Clin (Barc)</title>
		<imprint>
			<biblScope unit="volume">138</biblScope>
			<biblScope unit="page" from="650" to="e655" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b228">
	<analytic>
		<title level="a" type="main">The outcomes of using colistin for treating multidrug resistant Acinetobacter species bloodstream infections</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Lim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">O</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">Y</forename><surname>Jeong</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Korean Med Sci</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="325" to="e331" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b229">
	<analytic>
		<title level="a" type="main">Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia?</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Tasbakan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Pullukcu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">R</forename><surname>Sipahi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">I</forename><surname>Tasbakan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Aydemir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Bacakoglu</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Chemother</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="345" to="e349" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b230">
	<analytic>
		<title level="a" type="main">Prognosis of adult patients with bacteremia caused by extensively resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Tseng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">L</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chie</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Diagn Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="181" to="e90" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b231">
	<analytic>
		<title level="a" type="main">The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Ye</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">S</forename><surname>Leu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Chiang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">T</forename><surname>Huang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="351" to="e61" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b232">
	<analytic>
		<title level="a" type="main">The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">T</forename><surname>Amat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gutierrez-Pizarraya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Machuca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Gracia-Ahufinger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Perez-Nadales</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Torre</forename><forename type="middle">-</forename><surname>Gimenez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="630" to="e634" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b233">
	<analytic>
		<title level="a" type="main">Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections</title>
		<author>
			<persName><forename type="first">A</forename><surname>Batirel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">I</forename><surname>Balkan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Karabay</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Agalar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Akalin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Alici</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Eur J Clin Microbiol Infect Dis</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="1311" to="e1322" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b234">
	<analytic>
		<title level="a" type="main">Colistin versus colistin combined with ampicillinsulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study</title>
		<author>
			<persName><forename type="first">D</forename><surname>Makris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Petinaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Tsolaki</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Manoulakas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mantzarlis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Apostolopoulou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Indian J Crit Care Med</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="67" to="e77" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b235">
	<analytic>
		<title level="a" type="main">Treatment outcomes of colistin-and carbapenem-resistant Acinetobacter baumannii infections: an exploratory subgroup analysis of a randomized clinical trial</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Dickstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lellouche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ben</forename><surname>Dalak Amar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Schwartz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Nutman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Daitch</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="769" to="e76" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b236">
	<analytic>
		<title level="a" type="main">Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial</title>
		<author>
			<persName><forename type="first">Durante-Mangoni E</forename><surname>Signoriello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Andini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Mattei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename></persName>
		</author>
		<author>
			<persName><forename type="first">De</forename><surname>Cristoforo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Murino</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">57</biblScope>
			<biblScope unit="page" from="349" to="e58" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b237">
	<analytic>
		<title level="a" type="main">Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii</title>
		<author>
			<persName><forename type="first">J</forename><surname>Garnacho-Montero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Amaya-Villar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gutierrez-Pizarraya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Espejo-Gutierrez</forename><surname>De Tena</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Artero-</forename><surname>Gonzalez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Corcia-Palomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Chemotherapy</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="225" to="e231" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b238">
	<analytic>
		<title level="a" type="main">Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial</title>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Park</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">H</forename><surname>Cho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">H</forename><surname>Jeong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Byun</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Glob Antimicrob Resist</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="66" to="e71" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b239">
	<analytic>
		<title level="a" type="main">Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria</title>
		<author>
			<persName><forename type="first">N</forename><surname>Petrosillo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Giannella</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Antonelli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Antonini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Barsic</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Belancic</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Antimicrob Agents Chemother</title>
		<imprint>
			<biblScope unit="volume">58</biblScope>
			<biblScope unit="page" from="851" to="e858" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b240">
	<analytic>
		<title level="a" type="main">Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">P</forename><surname>Freire</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Oliveira</forename><surname>De</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Campagnari</forename><surname>Bueno</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Camargo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename></persName>
		</author>
		<author>
			<persName><forename type="first">Kono</forename><surname>Magri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Asg</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="352" to="e358" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b241">
	<analytic>
		<title level="a" type="main">Multidrugresistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Liao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">K</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">L</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Chang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page" from="196" to="e198" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b242">
	<analytic>
		<title level="a" type="main">Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">R</forename><surname>Yilmaz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Guven</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Guner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Kocak</forename><surname>Tufan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Izdes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tasyaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">A</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Infect Dev Ctries</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="476" to="e85" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b243">
	<analytic>
		<title level="a" type="main">Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenemresistant Acinetobacter baumannii ventilator-associated pneumonia</title>
		<author>
			<persName><forename type="first">H</forename><surname>Aydemir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Akduman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Piskin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Comert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Horuz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Terzi</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Epidemiol Infect</title>
		<imprint>
			<biblScope unit="volume">141</biblScope>
			<biblScope unit="page" from="1214" to="e1222" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b244">
	<analytic>
		<title level="a" type="main">Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Lopez-Cortes</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Cisneros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fernandez-Cuenca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Bou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Tomas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Garnacho-Montero</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Antimicrob Chemother</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="3119" to="e3126" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b245">
	<analytic>
		<title level="a" type="main">Epidemiology, clinical characteristics and outcomes of extensively drugresistant Acinetobacter baumannii infections among solid organ transplant recipients</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">K</forename><surname>Shields</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Gillis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">J</forename><surname>Kwak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">P</forename><surname>Silveira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">C</forename><surname>Massih</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">PLoS One</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">52349</biblScope>
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b246">
	<analytic>
		<title level="a" type="main">Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?</title>
		<author>
			<persName><forename type="first">F</forename><surname>Simsek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Gedik</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">T</forename><surname>Yildirmak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">E</forename><surname>Iris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Turkmen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ersoy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Med Microbiol</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="448" to="e52" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b247">
	<analytic>
		<title level="a" type="main">Extended-spectrum beta-lactamase-producing Escherichia coli isolation among older adults: epidemiology and outcomes</title>
		<author>
			<persName><forename type="first">S</forename><surname>Farooq</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Hayakawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Marchaim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Pogue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">S</forename><surname>Kaye</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Infect Control</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="page" from="565" to="e568" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b248">
	<analytic>
		<title level="a" type="main">Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Freeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Mcbride</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Nisbet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">D</forename><surname>Gamble</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Williamson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Taylor</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Infect Dis</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="e371" to="e374" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b249">
	<analytic>
		<title level="a" type="main">Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European Society of Clinical Microbiology and Infectious Diseases</title>
		<author>
			<persName><forename type="first">J</forename><surname>Rello</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sole-Lleonart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Rouby</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Chastre</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Blot</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Poulakou</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Microbiol Infect</title>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="page" from="629" to="e639" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b250">
	<analytic>
		<title level="a" type="main">Infectious diseases society of America guidance on the treatment of extendedspectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenemresistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficultto-treat resistance (DTR-P. aeruginosa)</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Aitken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Duin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">72</biblScope>
			<biblScope unit="page" from="169" to="e83" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b251">
	<monogr>
		<title level="m" type="main">Infectious diseases society of America guidance on the treatment of AmpC blactamase-Producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">D</forename><surname>Tamma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">L</forename><surname>Aitken</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Bonomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">J</forename><surname>Mathers</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Van Duin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Clancy</surname></persName>
		</author>
		<ptr target="https://www.idsociety.org/practice-guideline/amr-guidance-2.0/" />
		<imprint>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b252">
	<analytic>
		<title level="a" type="main">International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Paterson</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Von</forename><surname>Gottberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Mohapatra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Casellas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Goossens</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Ann Intern Med</title>
		<imprint>
			<biblScope unit="volume">140</biblScope>
			<biblScope unit="page" from="26" to="e32" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b253">
	<analytic>
		<title level="a" type="main">Ceftolozane/tazobactam plus metronidazole for complicated intraabdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)</title>
		<author>
			<persName><forename type="first">J</forename><surname>Solomkin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Hershberger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Miller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Popejoy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Friedland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Steenbergen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Infect Dis</title>
		<imprint>
			<biblScope unit="volume">60</biblScope>
			<biblScope unit="page" from="1462" to="1e71" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b254">
	<analytic>
		<title level="a" type="main">Use of noncarbapenem antibiotics to treat severe extended-spectrum beta-lactamaseproducing Enterobacteriaceae infections in intensive care unit patients</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">E</forename><surname>Luyt</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Faure</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Bonnet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Besset</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Junot</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Int J Antimicrob Agents</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="547" to="e52" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
